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ABSTRACT
Dengue virus (DENV) infection is the most prevalent arthropod-borne virus
disease. There are estimated 100 million symptomatic cases of dengue disease per year
worldwide. A lack of effective antiviral therapies or vaccines makes DENV infections
a major global health concern. Therefore, understanding the viral and host factors
contributing to the disease pathogenesis is critical. DENV has been shown to
effectively counteract host innate immune mechanisms. In particular, DENV protease,
NS3 has emerged as an inhibitor of host cellular signaling by targeting crucial host
proteins. Here we identified RIPK1 as a novel target of DENV NS3. RIPK1 is a
central mediator of innate immune regulation downstream of TNFR1, TLR3, TLR4,
RIG-I, and MDA-5. The outcomes of RIPK1-mediated inflammatory signaling include
NF-kB and MAPK activation and IRF3/IRF7 phosphorylation. RIPK1 also regulates
cell death signaling by modulating extrinsic apoptosis and necroptosis.
We observed that RIPK1 levels were significantly decreased in numerous cell
types with DENV infection. DENV NS3 was responsible for decreased RIPK1 levels
as shown by overexpression experiments. NS3 protease activity was fundamental for
this effect, because the overexpression of a catalytically inactive protease mutant
(NS2B3-S135A) did not result in a significant RIPK1 reduction. Additionally, both
wild type and protease mutant NS3 physically interacted with RIPK1 as shown by coimmunoprecipitation experiments. Consequently, DENV inhibited NF-kB activation
downstream of TNFR1 and TLR3 receptors by targeting RIPK1. Furthermore, we
detected that DENV did not induce necroptosis and further suppressed TNFR1-

induced necroptosis. Our findings add RIPK1 to the list of host proteins targeted by
DENV NS3 and expand the knowledge of strategies used by DENV to evade innate
immune responses. Manipulation of host cell RIPK1 signaling by DENV may
contribute to disease pathogenesis.
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PREFACE
The following dissertation has been prepared in manuscript format according
to the guidelines of the Graduate School of the University of Rhode Island. The
dissertation includes five chapters: Chapter 1, Introduction. Chapter 2, “Virus
inhibition of RIPK1-mediated innate immune signaling” prepared for submission to
mBio. Chapter 3, “Dengue virus downregulates TNFR1- and TLR3-stimulated NF-𝛋B
activation by targeting RIPK1” was prepared for submission to PLOS PATHOGENS.
Chapter 4, “Additional mechanisms and implications of RIPK1 downregulation by
DENV.” Chapter 5, Conclusions.
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CHAPTER 1
Introduction
Dengue Epidemiology
Dengue virus (DENV) infection, the most prevalent arthropod-borne virus
disease, represents a major global human health concern. DENV is endemic to more
than 100 countries in the world (Fig 1). Three billion people in tropical and subtropical
regions in the world are at a higher risk of getting infected with DENV. Approximately
50-100 million people are reported to exhibit symptoms due to DENV infections,
annually. The majority of infected individuals develop a mild febrile illness, but
approximately 500,000 clinical cases result in more severe dengue hemorrhagic fever/
dengue shock syndrome leading to 25-50,000 deaths per year (1,2) . Significantly, the
incidence has increased 30-fold in the last 50 years due to accelerating geographical
spread of the virus. This is evidenced by the identification of new cases of dengue
fever in Florida (USA), France, Spain and Japan in higher latitude regions (3,4).
The primary vector of the DENV is a female Aedes aegypti mosquito. These
mosquitos feed on the blood of humans primarily during the daytime. A. aegypti get
the virus after biting an infected individual. Following 8-10 days of virus incubation,
an infected mosquito is capable of disseminating the virus to susceptible individuals
for the rest of its life time (5).
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Figure 1. World distribution of Dengue in 2016
https://www.who.int/denguecontrol/epidemiology/en/

2

Dengue disease
DENV infections are caused by four closely related serotypes (DENV 1, 2, 3, 4).
Immune responses following primary DENV infection fully protect against the DENV
serotype that caused the primary infection, but only partially, and transiently, protect
against heterologous serotypes (6). DENV infection may result in asymptomatic or
symptomatic manifestations. Symptomatic cases constitute ~20% of infections.
Symptomatic infections result in a broad spectrum of effects including febrile illness ,
which may be uncomplicated (dengue fever, DF) or progress to a potentially fatal
disease, such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS)
(7,8). DF is a mild “flu-like” illness, which could appear 3-10 days after virus
infection via a mosquito bite. Other symptoms associated with DF are retro-orbital
pain, intense headache, intense joint and muscle pain and nausea (9,10). Even though
a majority of patients are able to recover completely after the febrile phase, some
(~3%) develop severe disease. DHF is distinguished from DF by the appearance of
vascular permeability, plasma leakage and bleeding manifestations. Thrombocytopenia
and coagulopathy are also associated with severe disease. Severe plasma leakage can
result in hypovolemic shock (4). These symptoms may lead to organ impairment and
death of the patient. DHF is often associated with hepatomegaly and histopathological
reports of human fatal dengue cases indicate that the liver, spleen and lymph nodes are
target organs of infection (11).
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Factors contributing to Dengue Disease pathogenesis
Various factors are considered to contribute to the dengue disease severity. For
example, virus virulence, preexisting dengue antibodies, immune dysregulation and
host genetic susceptibility are factors known to be associated with dengue
pathogenesis. Paradoxically, severe dengue symptoms (e.g., plasma leakage) are not
observed when the viremia is at the highest, but when the virus is being cleared,
suggesting that host immune responses play an adverse role in disease pathogenesis
(12). Some of the components that are known to contribute to dengue pathogenesis are
discussed below.

1. Antibody-dependent enhancement
Multiple cohort studies have identified secondary DENV infection as an
epidemiological risk factor for severe dengue (13–15). However, a majority of tertiary
and quaternary infections are clinically silent or mild (16). A potential reason for
increased risk with the secondary infection is the presence of non-neutralizing, crossreactive antibodies generated against the primary infection. These antibodies bind the
second virus (heterologous serotype) and facilitate infection via Fc𝛾 receptors
expressed on cell surfaces. This phenomenon is known as “Antibody-dependent
enhancement (ADE)” (Fig 2). Thus, increased numbers of virus-infected cells due to
ADE may increase disease pathogenesis in secondary infection (17,18). The only
licensed vaccine against dengue, Dengvaxia, increased the risk of severe disease in
children when they were subsequently infected by DENV. The vaccination itself acted
as a primary infection inducing antibody production, which enhanced virus infection
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in the event of a secondary infection, perhaps via ADE (19).

Figure 2. The mechanism of Antibody-Dependent Enhancement
(Adapted from Puccionoi-Sohler et al., 2015)

2. T cell mediated immunity
T cell mediated immune responses during the secondary infection have been
proposed to contribute to the severity of dengue disease (18). Virus-specific CD8+
cytotoxic T lymphocytes (CTL) directly lyse virus-infected antigen-presenting cells
(APC). Additionally, CTL secrete cytokines such as IFN𝛾, which enhances
cytotoxicity of CTLs and increases their motility (20). Other cytokines secreted by T
cells, such as IL-8 and IL-9, stimulate recruitment and activation of other immune
cells. Thus, T cells are important for controlling DENV infections. However, with the
encounter of a secondary DENV infection there is a tendency toward expansion of the
memory T cell repertoire from the previous infection. These T cells may exhibit a
lower avidity to the current serotype and induce “skewed” immune responses, which
could be deleterious to the host (18). These responses may result in an altered cytokine
profile which could exacerbate the disease. This is evidenced by the detection of
5

increased T cell activation in DHF than in DF patients. Patients experiencing severe
dengue have altered cytokine profiles as compared to patients exhibiting milder
disease (21). Taken together, these data indicate that the level of T cell response
correlates with the disease severity (22).

3. Cytokine dysregulation
During primary DENV infection inflammatory cytokines are secreted from
infected cells, which is important for attracting NK cells, T and B cells and the
initiation of adaptive immunity. The level of cytokines released during primary
infection is not likely detrimental to the host. However, during secondary infection
cross-reactive T cells from the primary infection are expanded and secrete
inflammatory cytokines rapidly (18). Studies have demonstrated that proinflammatory cytokines and vasoactive cytokines are elevated in patients with DHF
(23). Levels of TNF⍺, IL-1β, IFN𝛾, IL-8, IL-6, IL-10 and free VEGF-A were elevated
in patients with DHF compared to patients with DF (10,18,24–26). The magnitude of
the cytokine levels correlated with the disease severity (18,23). These cytokines,
especially TNF⍺, increase endothelial vascular permeability contributing to the plasma
leakage syndrome (23,27).

4. Complement activation
Complement activation as a result of immune complexes (virus-antibody) or
immune activation and cytokine production has been proposed to be involved in the
pathogenesis of plasma leakage in DHF (28). A significant reduction in complement
protein levels with a concurrent increase in complement fragments was reported in
6

patients with DHF. The degree of the complement activation correlated with the
severity of the disease (29). Certain complement fragments such as C3a and C5a are
known to enhance vascular permeability contributing to the plasma leakage seen in
DHF. Antibodies to the DENV non-structural protein 1 (NS1) were demonstrated to
form immune complexes with DENV NS1 protein in the circulation and also on the
surface of infected cells leading to complement activation (30). Therefore, rapid
complement activation during secondary infection is likely to contribute to the severity
of dengue disease.
5.

Viral virulence
Differences in virulence in naturally circulating DENV strains and serotypes are

speculated to contribute to dengue disease (31). Viral genetic differences are reported
to be associated with differences in virulence between DENV strains (32–34). A study
done on children with acute DENV infections reported secondary DENV2 caused
more severe disease than DENV1 or DENV4, suggesting that virus genotype affects
outcome (35). Enhanced pathogenicity was attributable to increased replication of
DENV2 compared to DENV1. Another study found that primary infection with
DENV3 from the south east Asia region (SEA) and secondary infection with DENV2,
DENV3 and DENV4 also from the SEA region, as well as DENV2 and DENV3 from
non-SEA region increased the risk of severe dengue disease (36). To make things
more complicated, extensive diversity is seen within DENV serotypes resulting in
various genotypes. For example, among different DENV1 strains isolated from the
2014 Dengue outbreak in China (DENV1A-E), DENV1B had the highest replication
efficiency and the highest mortality in suckling mice (37). Therefore, virulence of
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different DENV strains is directly associated with disease severity.
6. Other factors
Genetics of the host may also contribute to disease severity. Genome wide
association studies found polymorphisms within MICB (Major histocompatibility
complex class I polypeptide-related sequence B) and PLCE1 (phospholipase C,
epsilon 1) significantly associated with DSS (38). Human leucocyte antigen (HLA) is
one of the genetic factors that impacts the immune responses against DENV. DENV
infection has been reported to induce the expression of HLA class I and II molecules
on infected cells. Thus, immune responses generated from peptides presented by HLA
may be responsible for the immunopathology of DENV infection (39). A study done
on DENV patients and healthy controls from Malaysia reported that HLA-B*53 is
associated with disease susceptibility, while HLA-A*03 and HLA-B*10 may confer
protection (40).
Furthermore, cross-reactivity of anti-NS1 antibodies with thrombocytes,
endothelial cells and fibrinogen is believed to contribute to hemorrhage and
coagulopathy (41). Some chronic diseases such as diabetes mellitus also likely
increase the risk for severe dengue disease (42). One speculation for this effect is the
further damage of the impaired vasculature in diabetic patients during dengue. Overall
severe dengue disease is a result of complex interactions between the virus and the
host. However, dissecting the role of some host factors such as host immune responses
is complicated by the lack of an experimental animal model that is able to mimic the
full spectrum of the disease seen in humans.
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DENV structure
DENV is an icosahedral, lipid-enveloped virus. Mature DENV is reported to
be 500 Å in diameter (43). DENV contains a positive-sense single-stranded RNA
genome of 10.5kb, which can be directly translated inside a living cell. DENV RNA is
a dynamic molecule and adapts both linear and circular conformations in an infected
cell (44). The DENV genome codes for 3 structural proteins and 7 non-structural
proteins (Fig 3).

Figure 3. Structural and non-structural proteins encoded by the DENV genome
(Maririang et al., 2013)

The DENV structure is formed by three structural proteins coded by its
genome. They are the capsid protein (C), prM (membrane) and the envelope protein
(E). The DENV genome also encodes for seven nonstructural proteins: NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5. Capsid (C) is a highly basic protein with ~100
amino acids. Capsid protein is involved in packaging the viral genome and forming
the nucleocapsid core (45,46). prM (~165 amino acids) and E (~495 amino acids) are
glycoproteins each having two transmembrane helices (43). prM is cleaved by host
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furin during the maturation of virus particles yielding the pr peptide and the M protein
(47). The E protein contains one or more cellular receptor binding sites (48).
NS1 protein is involved in virus replication, and also can reside on the host cell
surface or be released from the cell in a hexameric conformation (49,50). NS1 can be
used as a diagnostic marker to detect early dengue since it is secreted into the blood
before the production of DENV-specific antibodies (51). The concentration of NS1 in
serum correlates with severity of the disease (30). NS1 is also known to activate the
NF-𝛋B pathway downstream of TLR4 (52).
NS2A is a hydrophobic protein that is cleaved by host proteases at the N
terminus and by the DENV protease NS3, at the C terminus (53). NS2A is reported to
be involved in viral replication, virus assembly, immune evasion and disease
pathogenesis (54). NS2B is also a hydrophobic protein that acts as a cofactor for NS3
proteolytic activity (55). The N-terminal 180 acids of NS3 contains a serine protease
domain (56). The C-terminal domain of NS3 is involved in viral RNA replication (57).
The region spanning from amino acids 180 to 618 of NS3 contains a RNA helicase
and a NTPase motif (57,58).
NS4A is cleaved from NS3 at the N terminus and from the 2K fragment at the
C terminus by NS3. NS4A is essential for viral replication (59). NS4B is a
hydrophobic transmembrane protein which is important for viral replication (60).
However, studies on the exact role of NS4B in viral replication and pathogenesis are
still needed. NS5 is the largest protein encoded by the DENV genome. NS5 has
methyltransferase and RNA-dependent RNA polymerase functions. NS5 is also
reported to be translocated to the host cell nucleus where it manipulates the host cell’s
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splicing machinery (61). Interestingly, NS5 and other DENV proteins are implicated
in host innate immune evasion by different strategies, which will be discussed later in
the Chapter 1.

DENV life cycle
DENV infects a range of human cells including dendritic cells, macrophages,
monocytes, B cells, T cells, hepatocytes, epithelial cells and endothelial cells (62–64).
DENV enters human cells via receptor mediated endocytosis. DC-SIGN, mannose
receptor, CD14, Fc𝛾 receptor and heparan sulfate are known to act as receptors for
DENV attachment and entry (65–69). The acidic pH in endosomes triggers fusion of
viral and endosomal membranes releasing the viral genome into the cytosol (70,71).
Since the DENV genome is a plus strand RNA, protein translation can initiate
immediately following the release of the genome. The genome is translated into one
polypeptide that gets processed into individual viral proteins by host and viral
proteases. Viral replication and assembly take place in membranous structures
associated with the ER (72). Immature virus particles contain E, prM, the lipid
membrane and the nucleocapsid. Since these immature particles are not able to induce
host cell fusion, they are noninfectious. After assembly, the immature virions exit from
the ER through the trans-Golgi network (Fig 4). During this process, they undergo
protease- and pH-dependent maturation rendering the virions mature (73,74). The E
protein undergoes positional reorganization and prM is cleaved by the cellular
endoprotease, furin (47). The resulting small membrane-anchored M portion remains
associated with the virion. The cleavage of prM and the disassociation of the pr
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peptide are important for fusion with the host cell membranes during subsequent
virion entry into a new cell (47,70).

Figure 4. DENV life cycle. The DENV attaches to receptors on host cells and
internalizes by receptor mediated endocytosis. In endosomes, due to the acidic pH,
viral and endosomal membranes fuse, releasing the viral genome into the cytosol.
Viral RNA translation and replication take place at the membranous structures
associated with the endoplasmic reticulum. Assembled viral particles exit the host cell
via the trans-Golgi apparatus. (Adapted from Gerald G et al., 2017)

DENV evasion of innate immune responses
During the DENV life cycle, viral RNA and viral proteins (pathogenassociated molecular patterns/ PAMPs) are released into the host cell cytosol. Pattern
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recognition receptors in the host cell such as TLR3 (Toll like receptor 3), TLR4 (Toll
like receptor 4), RIG-I (Retinoic acid-inducible gene 1 like receptor) and MDA-5
(Melanoma differentiation associated protein 5) recognize these PAMPs and initiate
signaling cascades that culminate in the production of antiviral effectors such as
interferons (IFN) and pro-inflammatory cytokines. Once secreted, IFNs will bind to
IFNRs (IFN receptor) on both infected and uninfected cells and signal for the
induction of “interferon-stimulated genes” (ISG) via the JAK-STAT (Janus kinaseSignal transducer and activator of transcription) pathway (75–77). DENV has evolved
different strategies to inhibit these signaling cascades to evade host immune responses
(78).
Cellular mRNA is post-transcriptionally capped at the 5’ end with a N-7
methyl guanosine and one or two 2’-O methyl nucleotides (79,80). DENV NS5 also
catalyzes both N-7 and 2’-O methylations sequentially to mimic cellular mRNA and to
hide sensing by host Pattern Recognition Receptors/ PRRs (81–83).
DENV generate detectable amounts of intracellular dsRNA as an intermediate
of their replication (84). The localization of DENV dsRNA is important for
recognition by PRRs. However, DENV RNA is reported to be concealed in DENVinduced membranous structures up to 72hrs post-infection (85). This may give
DENV an added advantage to hide from host immune responses. Once these RNA
species leak into the cytosol they can be recognized by RIG-I/MDA-5 and TLR3
receptors. RIG-I/MDA-5 signal for IFN production, NF-𝛋B and MAPK activation via
the mitochondrial associated protein MAVS (Mitochondrial antiviral signaling
protein). It has been reported that DENV NS4A interacts with MAVS and blocks the
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association of RIG-I and MAVS, inhibiting IFN production (86). Another study
found that DENV NS2A and NS4B inhibited RIG-I/MDA-5-mediated IFN
production by blocking TBK1 activation downstream of MAVS (87).
STING (Stimulator of IFN genes) is an adapter molecule in the cGAS-DNA
(Cyclic GMP-AMP synthase) sensing pathway. Activation of the cGAS/STING
pathway leads to the production of IFNs via IRF phosphorylation and proinflammatory cytokine production via NF-𝛋B activation (88). STING is also known to
interact with RIG-I and MAVS to enhance anti-viral responses (89,90). DENV NS2B3
protease complex is known to interact with and cleave STING, downregulating IFN
responses (91). DENV protease cofactor NS2B is also known to decrease cGAS levels
by interacting with it and promoting cGAS for autophagosome-mediated degradation
(92).
DENV NS4B protein inhibits IFN-induced STAT1 phosphorylation and
nuclear translocation, impairing the transcriptional activation of the ISGF3 (Interferon
stimulated gene factor 3) complex that is important for the expression of antiviral
genes (93). Moreover, DENV NS5 is known to interact with STAT2 and promote it
for proteasomal degradation, impeding ISGF3 activation (94).
The mitochondrion has emerged as an important organelle in antiviral
signaling. DENV has been reported to manipulate mitochondrial dynamics to
counteract antiviral responses and establish infections. DENV NS2B3 interacted with
and cleaved mitochondrial proteins MFN1 and MFN2 (95). This cleavage resulted in
fission of mitochondria and inhibition of MAVS-mediated antiviral responses. In
contrast, studies done by our group have shown that mitochondrial elongation as a
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result of decreasing levels of mitochondrial protein DRP1 resulted in increased viral
replication (96). Consistent with these results another study demonstrated that DENV
NS4B inhibited DRP1 activation leading to mitochondrial elongation and impairment
of RIG-I-mediated immune responses (97).
DENV was also shown to block NF-𝛋B activation downstream of TNFR and
TLR3 by unknown mechanisms (98,99). The attenuation of NF-𝛋B activation resulted
in diminished pro-inflammatory cytokine production. Nevertheless, how this
inhibition was achieved by DENV was not known.
Collectively, these studies demonstrate that DENV proteins and RNA
antagonize host innate immune responses and further damage infected cells. It’s
plausible to assume that DENV may defeat host immunity at the first line of defense.
The inhibition of innate immune mechanisms in the initial phase of infection may
contribute to disease pathogenesis. However, there are still many unanswered
questions related to the evasion of innate immune mechanisms by DENV.

Objectives of the dissertation
DENV has evolved efficient strategies to counteract innate immune
mechanisms. Particularly, individual DENV proteins are shown to target crucial host
proteins to inhibit signaling pathways. RIPK1 (Receptor interacting protein kinase 1)
has emerged as a central regulator in cell death and inflammation. Various viruses
have evolved strategies to inhibit RIPK1-mediated signaling. However, no studies had
been done to investigate RIPK1-mediated signaling in DENV infection. We observed
a decrease in RIPK1 levels during DENV infection. Therefore, the overall goal of this
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dissertation was to understand the effect of RIPK1-mediated signaling in DENV
infection. In particular, we hypothesized that RIPK1-mediated signaling will be
inhibited by DENV. The specific aims of this study are as follow:
Specific aim 1: Determining the mechanism by which DENV infection causes
decreased levels of RIPK1
Specific aim 2: Determining the role of DENV in RIPK1 mediated NF-𝛋B activation
Specific aim 3 Determining the role of RIPK1 in cell death during DENV infection
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Introduction
RIPK1 was first discovered by Stanger et al. as a Fas binding protein important
for programmed cell death in response to Fas ligation (1). Since then it has emerged as
a central molecule regulating several biological pathways leading to cell death and
inflammation. Its role is of particular interest in immune regulation. The primary goal
of the immune system is to protect the host from invading pathogens. For this purpose,
the innate immune system in particular has evolved multiple signaling networks that
culminate in the production of cytokines, chemokines, and interferons. RIPK1 is
located at the intersection of several signaling pathways and initiates signaling from
both membrane-bound receptors and intracellular pattern recognition receptors that are
important in pathogen recognition. Consequently, pathogens including viruses target
RIPK1 to evade host immune responses. Thereby these pathogens have managed to
establish effective infections. Accordingly, there is an unexpected diversity in the
strategies exploited by viruses to target RIPK1. This review aims to summarize current
knowledge of RIPK1 signaling in innate immune regulation. Furthermore, we explore
various mechanisms utilized by viruses to inhibit RIPK1 signaling, with the goal of
understanding subsequent outcomes that ultimately benefit viruses.

The structure of RIPK1
RIPK1 is a member of the receptor-interacting serine/threonine family. RIPK1
harbors an N-terminal kinase domain, an RHIM (RIP homotypic interaction motif)containing intermediate domain (ID), and a C-terminal death domain (DD) (1–
3)(Fig.1). The kinase activity and the ability of RIPK1 to interact with other DD-
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containing and RHIM-containing proteins make it a multifunctional protein involved
in many cellular pathways (4,5). RIPK1 mediates signaling downstream of TNFR1,
TLR3, TLR4, RIG-I/MDA-5, and ZBP1. These signaling events culminate in NF-𝛋B-,
MAPK-, and IRF3/7-mediated cytokine, chemokine, and interferon production, which
is vital for controlling infections. In the sections below, we discuss in detail major
signaling events mediated by RIPK1.

Figure 1. Domain structure of RIPK1. RIPK1 consists of an N-terminal kinase
domain, an intermediate domain and a C-terminal death domain. (Adapted from
Ofengeim D & Yuan J, 2013)

RIPK1 signaling downstream of TNFR1
TNFɑ ligation with TNFR1 (TNF Receptor 1) initiates signaling cascades
leading to NF-𝛋B activation, MAPK activation, extrinsic apoptosis and necroptosis
(Fig 2). RIPK1 acts as a critical signal transducer in the NF-𝛋B pathway downstream
of TNFR1. NF-𝛋B signaling is vital for the regulation of the immune system. NF-𝛋B
family members (p50, p52, RelA, c-Rel, and RelB) regulate the transcription of proinflammatory cytokines and anti-microbial effectors such as IL-6, IL-8, IL-10, CCL5,
TNFɑ, CCR5, etc. (7). They also regulate genes involved in cellular proliferation,
differentiation, and survival (8–11). Thereby, NF-𝛋B transcription factors regulate
various aspects of both innate and adaptive immune responses. Pathogens have
evolved mechanisms to downregulate the NF-𝛋B activation in order to evade the host
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immune and inflammatory responses (12). For example, human rotavirus and DENV
antagonize the NF-𝛋B pathway leading to downregulated cytokine responses (13,14).
The role of RIPK1 in TNFɑ signaling is well studied. Upon TNFɑ ligation,
TRADD (TNFR1 associated death domain protein) binds to the cytoplasmic death
domain (DD) of TNFR1 (TNF receptor 1). TRADD recruits TRAF2/ TRAF5 (TNF
associated factors) along with RIPK1 and cIAP proteins (Cellular inhibitor of
apoptosis). Ubiquitination of RIPK1 by TRAF2 and/or cIAPs creates a platform for
recruiting TAK1, TAK binding proteins (TAB1 and TAB2) and the IKK complex
(NEMO, IKKɑ, IKKß) (15–17).This protein complex downstream of TNFR1 is
known as complex I (Fig 1). The IKK complex phosphorylates I𝛋B⍺ and promotes it
for proteasomal-mediated degradation. This liberates NF-𝛋B transcription factors,
from the inhibitor I𝛋B⍺ and allows them to translocate into the nucleus resulting in
induction of antiviral genes. Studies done on mice with a genetic mutation in RIPK1
destroying its kinase activity, demonstrated intact NF-𝛋B responses following TNFɑ
stimulation.

Treatment with Necrostatin-1, a specific inhibitor of RIPK1 kinase

activity did not affect TNFɑ-induced NF-𝛋B responses in mice (18,19). These data
indicate that the kinase activity of RIPK1 is dispensable for NF-𝛋B activation.
MAPKs (Mitogen associated protein kinases) consist of three groups, known
as Erk1/2 (Extracellular signal-regulated kinases), JNKs (Jun N-terminal kinases), and
p38 (20,21). The MAPK pathway culminates in AP-1 transcription and induces the
expression of genes important for host defense during pathogen invasion. AP-1
regulates the expression of pro-inflammatory cytokines and chemokines such as IL-2,
IFN𝛾, TNF⍺, IL-6, IL-4, GM-CSF, CXCL8. Thereby AP-1 regulates leukocyte
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activation and differentiation (22,23). Therefore, numerous pathogens target the
MAPK pathway to evade the aforementioned host immune responses. For example,
DENV did not activate Erk 1/2 phosphorylation and even impaired the basal level of
p-Erk1/2 in A549 cells (14).
RIPK1 is placed at a crucial point in MAPK signal transduction downstream
of TNFR1. RIPK1 ubiquitination in complex I by TRAF2 or cIAPs leads to the
assembly of a TAK1, TAB2, TAB3 complex. TAK1 phosphorylates MAPKs such as
p38, JNK, and Erk leading to the expression of additional transcription factors, ATF2,
JUN, and TCF, which translocate into the nucleus facilitating AP-1 transcription (24).
The ID of RIPK1 is necessary and sufficient for the activation of MAPKs upon TNF⍺
stimulation (25). Conversely, another study demonstrated that RIPK1 mediated TNF⍺induced p38 MAPK activation by recruiting MEKK3 (Mitogen-activated protein
kinase kinase kinase 3) to TNFR1 (26). The authors showed that RIPK1 transiently
interacted with MEKK3 upon TNF⍺ stimulation. Even though this interaction
occurred via the RIPK1 ID, the kinase activity of RIPK1 was important for a stable
interaction. A RIPK1- MEKK3 interaction was observed in cells expressing wild type
RIPK1 but not in cells expressing kinase-inactive RIPK1.These reports suggest that
there may be more than 1 routes of MAPK activation in complex I via RIPK1.
Targeted disruption of the rip1 gene (which codes for RIPK1) in Mouse embryonic
fibroblasts prevented p38 MAPK activation and IL-6 production in response to TNF⍺
(26).

exhibiting the vital role of RIPK1 in regulating MAPK-AP-1 signaling

downstream of TNFR1.
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RIPK1 signaling downstream of TLR3 and TLR4
Stimulation of toll like receptors (TLRs) can lead to potent innate immune
responses via NF-𝛋B activation. TLR4, the immune sensor for bacterial LPS, triggers
NF-𝛋B activation via either MyD88 (Myeloid differentiation primary response gene
88)-dependent or TRIF (TIR domain-containing adapter inducing interferon β )dependent signaling pathways (27,28). TLR3 participates in recognition of pathogenassociated double-stranded (ds) RNA and the synthetic analog of viral ds RNA, poly
(I:C). Unlike TLR4, TLR3 induces NF-𝛋B activation only via TRIF (29). In both
TLR3 and TLR4 signaling, TRIF interacts with RIPK1 via a conserved four amino
acid motif (VQLG) in the C-terminal RHIM domain of TRIF (30). TRIF also recruits
TRAF6 and TBK1 via its N terminus (29). These interactions result in IKK activation
and I𝛋B phosphorylation, liberating NF-𝛋B, which translocates to the nucleus and
initiates transcription of genes involved in immune responses (31). TRIF-RIPK1
interaction results in recruitment of TAK1 leading to the activation of MAPKs and
AP-1 activation leading to enhanced immune responses (32). Even though this
tethering of signaling molecules by RIPK1 (scaffolding function) is sufficient for NF𝛋B and MAPK activation, a RIPK1 kinase activity-dependent mechanism was
recently reported (33). The kinase activities of RIPK1 and RIPK3 promoted sustained
activation of Erk, cFos and NF-𝛋B in LPS-stimulated macrophages. Regulation was
induced in the absence of caspase 8 activity and was dependent on TRIF. Even though
the speculation is that this signaling initiated from a death signaling complex
involving RIPK1, (necrosome), the detailed molecular mechanism remains to be

31

elucidated. It is tempting to conjecture that similar RIPK kinase activity-dependent
signaling could occur downstream of TLR3 as well.
RIPK3 has been shown to inhibit RIPK1-mediated NF-𝛋B activation by
competitive binding to TRIF downstream of TLR3 and TLR4 (29). The RIPK3-TRIF
interaction could potentially inhibit RIPK1-driven MAPK activation, even though this
has not been investigated so far. Therefore, it could be of interest to study the effect of
RIPK3 on TLR3/TLR4-stimulated MAPK pathway.
TLR3 and TLR4 activate signaling pathways that culminate in the production
of IFNs and IFN-inducible genes through IRF3/IRF7 phosphorylation, which is
central to antiviral innate immune responses (34). Even though RIPK1 interacts with
TRIF, involvement of RIPK1 in TRIF-dependent IRF3/IRF7 signaling is somewhat
less clear. Overexpression of the RHIM domain of RIPK1 alone was sufficient to
induce TRIF-mediated NF-𝛋B activation as measured using a luciferase reporter.
However, the activity of an IFNβ luciferase reporter was not induced with
overexpression of either a WT or RHIM mutant RIPK1 (29). ISRE reporter luciferase
activity increased in HEK293 cells with overexpression of TRIF but not with
overexpression of RIPK1 (35). This RIPK1-independent response in IRF3/7
phosphorylation could be due to the ability of TRIF to directly interact with both IRF3
and the IRF3-activating kinase, TBK1 (31) However, RIPK1-dependent regulation of
IRF3/7 activation was shown by studies done by Hyun et al. (36). The authors
suggested that the Human T lymphotropic virus (HTLV-1) Tax protein prevented
TLR3-induced IRF3 phosphorylation by competitively binding to TRIF (36).
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Therefore, more mechanistic studies would be needed to resolve discrepancies
regarding RIPK1 regulation of IRF3/7 activation downstream of TLR3 and TLR4.

RIPK1 signaling downstream of RIG-I and MDA-5
The RNA helicases RIG-I (Retinoic acid-inducible gene 1) and MDA-5
(Melanoma differentiation-associated protein 5) are known to initiate signaling
pathways culminating in the production of type I interferons (IFN⍺, IFNβ, IFNε,
IFN𝛋) and pro-inflammatory cytokines during the early stages of viral infections (37).
It has been reported that RIG-I most strongly recognizes short 5’ppp dsRNA, while
MDA5 recognizes preferentially long dsRNA (38,39). RIG-I most potently detects
influenza viruses, filoviruses, and rhabdoviruses while MDA5 is essential for the
recognition of picornaviruses, arteriviruses, and hepatitis D virus (40–44). These
receptors are also involved in recognizing non-viral pathogens; MDA5 has been
reported to respond to Malaria parasites (45). Nevertheless, viruses have evolved
strategies to impair signaling downstream of RIG-I/MDA-5. For example, the DENV
protease NS3 was shown to cleave mitochondrial associated proteins MFN1 and
MFN2 impairing efficient RLR signaling (46). Influenza A H1N1 viral protein NS1
directly interacts with RIG-I and prevents its activation, inhibiting IFNβ production
(47).
RIPK1 is involved in NF-𝛋B, MAPK, IRF3 and IRF7 activation downstream
of RIG-I and MDA5. RIG-I and MDA5 signaling merge at the mitochondria through
MAVS (Mitochondrial antiviral signaling protein), which is located at the
mitochondrial membrane (48). TRADD and FADD are required to recruit RIPK1 to
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MAVS following RIG-I/MDA-5 stimulation (49).

RIPK1 signaling to NF-𝛋B

proceeds through the IKK complex, while signaling to IRF3/IRF7 proceeds through
TBK1 and IKKɛ (50,51).

Activation of MAPK downstream of RIG-I involves

TRAF2, TAK1, and the kinase activity of RIPK1 (52). RIG-I and MDA-5 activate
NF-𝛋B and p38 MAPK through a common upstream pathway involving RIPK1 and
only diverge downstream of TAK1. Therefore, RIPK1 functions as an essential
adaptor molecule in RIG-I and MDA-5 signal transduction by facilitating the
association of other proteins (51).

RIPK1 signaling in cell death - Ripoptocide
Viruses are obligate intracellular pathogens that require living cells. Hence,
cell death can be an important immune defense against infection. RIPK1 regulates cell
death pathways known as “ripoptocide” involving both apoptosis and necroptosis (53).
Apoptosis is a non-inflammatory form of cell death having morphological changes
such as cell shrinkage, chromatin condensation, and plasma membrane blebbing (54).
Apoptosis can be induced by extrinsic or intrinsic stimuli. Extrinsic apoptosis is
mediated by death receptors such as TNFR1 whereas intrinsic apoptosis is driven by
intrinsic stresses such as DNA damage, growth factor withdrawal, or ER stress leading
to mitochondrial outer membrane permeabilization (54,55). RIPK1 is involved in
regulating extrinsic apoptosis downstream of TNFR1. Deubiquitination of RIPK1
leads to the formation of a complex with Pro-Caspase 8 and FADD in response to
TNF⍺ stimulation, which is referred to as complex IIa (Fig 2) (6). Assembly of
complex IIa leads to auto-processing and maturation of pro-caspase 8 into caspase 8,
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which initiates extrinsic apoptosis. A similar complex known as the ripoptosome
assembles in response to TLR3 and TLR4 stimulation (56,57). The core of the
ripoptosome consists of RIPK1, FADD, and Caspase 8 (57). The ripoptosome can also
recruit additional proteins such as cFLIP (FLICE like inhibitory protein) and RIPK3
depending on the cell type and stimulus (57). As in complex IIa, the ripoptosome
promotes caspase 8 activation. Mature caspase 8, in turn, activates downstream
caspases such as caspase 3 resulting in extrinsic apoptosis. Active caspase 8 also
cleaves RIPK1 downstream of residue Asp 324 in the ID during apoptosis. The Cterminal 38kDa cleavage product generated from this cleavage is known to facilitate
interactions between FADD and TRADD, further contributing to extrinsic apoptosis.
The expression of RIPK1 mutants resistant to caspase 8 cleavage protected cells
against TNF⍺-induced apoptosis demonstrating the pro-apoptotic nature of cleaved
RIPK1 (58). The induction of apoptosis by RIPK1 contributes to virus clearance by
eliminating infected cells, however, it’s an immunologically silent form of cell death
because it does not cause inflammation.
Necroptosis is considered as an anti-viral defense mechanism because it can
initiate a strong pro-inflammatory response. Necroptosis is morphologically
characterized by swelling of organelles followed by plasma membrane rupture
(59)(60,61). Necroptosis protects the host both by limiting pathogen replication in
infected cells and by promoting inflammatory responses that stimulate host
adaptive immunity (62). Necroptotic cell death is driven by a protein complex known
as the "necrosome". The necrosome includes RIPK1 and RIPK3, which interact with
and phosphorylate each other. Activated/phosphorylated RIPK3 recruits and
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phosphorylates MLKL (Mixed lineage domain-like protein). Phosphorylated MLKL
forms tetramers, translocates to the cell membrane and further polymerizes to form
amyloid-like structures (63). These polymerization events result in cell membrane
permeabilization and cell lysis (64). How MLKL polymers disrupt membrane integrity
is unclear. Necrosomes are formed downstream of TNFR1, TLR3, and TLR4 in the
absence of caspase 8 activity. Even though RIPK1 participates in extrinsic apoptosis
and necroptosis, the loss of RIPK1 also sensitizes cells to TNF⍺-induced apoptosis
(65,66) perhaps due to NF-𝛋B inhibition. Therefore, a goal of future studies should be
to understand what factors regulate the final effects of RIPK1 leading to cell survival
or cell death. Additionally, whether RIPK1 signal for cell death downstream of RIG-I/
MDA-5 has yet to be explored.
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Figure 2. Signaling pathways mediated by RIPK1. TNFR1 stimulation leads to the
assembly of complex I, which signals for the NF-kB and MAPK activation. When
RIPK1 is deubiquitinated in the complex I, signaling is diverted into caspase 8
maturation and extrinsic apoptosis in complex IIa. In the absence of caspase 8 activity,
RIPK1 signaling results in induction of necroptosis. TLR4 and TLR3 stimulation
results in RIPK1-regulated NF-kB and MAPK activation. Extrinsic apoptosis could
take place in the ripoptosome downstream of TLR3 and TLR4. When caspase 8
activity is depleted, RIPK1 signals for necroptosis downstream of TLR3 and TLR4.
RIG-I/MDA-5 signals for IFN induction, NF-kB and MAPK activation via RIPK1.

Viral strategies in modulating RIPK1 signaling
RIPK1 is placed at a crucial point in controlling cell death and inflammation.
RIPK1-mediated signaling governs the outcome of signaling pathways initiated by
TNFR1, TLR3, TLR4 and RIG-I/MDA-5 by signaling for NF-kB activation, and
MAPK and IRF3/7 phosphorylation. In the event of an infection, activation of these
pathways results in release of pro-inflammatory cytokines, chemokines and interferons
setting an antiviral state. RIPK1 is also involved in destroying replication niches of
pathogens by signaling for extrinsic apoptosis or necroptosis. Therefore, RIPK1 has
emerged as an attractive target for inhibition by viruses. Here we have summarized
current knowledge in viral strategies that modulate RIPK1-mediated signaling by virus
family.
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1. Herpesviruses
Members of the Herpesviridae family have double stranded DNA genomes.
They are categorized into ⍺, β, and γ herpesviruses based on their host range, genome
and replication strategies (67). Most vertebrates get infected with one or more
herpesviruses during their lifetime. Herpesviruses commonly establish a life-long
infection in the host. Human herpes simplex virus-1 (HSV-1) , an ⍺ herpesvirus, is
associated with genital herpes, herpes encephalitis and ocular HSV causing blindness
(68). Human cytomegalovirus (CMV) is a β herpesvirus that causes a wide spectrum
of pathological outcomes. Congenital CMV infections are often associated with
serious

complications

including

microcephaly

and

mental

retardation.

Immunocompromised patients can develop encephalitis, pneumonitis and graft
rejection as a result of CMV infections (69). Epstein-Barr virus (EBV) is a human γherpesvirus. It’s the primary cause of infectious mononucleosis. EBV infections are
also associated with ~200,000 malignancies (Burkitt’s lymphoma, non-Hodgkin’s
lymphoma, nasopharyngeal carcinoma, gastric adenocarcinoma) worldwide every
year (70). Several members of the herpesvirus family have been shown to impair
RIPK1-mediated signaling.

1.1 Herpes simplex virus-1 (HSV-1)
Murine HSV-1 induces necroptosis, which restricts viral propagation (71). In
contrast, human HSV-1 has evolved to escape necroptosis-mediated restriction by at
least three mechanisms. In one mechanism, the human HSV-1 protein ICP6
promotes RIPK1 aggregation and then its degradation by the autophagosome, a
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process known as aggrephagy (72). A conserved motif in all the human
herpesviruses known as the “induced protein aggregation motif (IPAM)” is needed
for this aggregate formation. Expression of wild-type ICP6 alone was sufficient to
induce aggregate formation in human fibroblasts while expression of a mutant IPAM
(DIPAM) ICP6 failed to do so (73). However, no experiments were shown to
indicate if IPAM of ICP6 was important for RIPK1 interaction. In a second
mechanism it was shown that HSV-1 proteins ICP6 and ICP10 both harbor RHIM
domains and disrupt the RIPK1-RIPK3 association by competing for RIPK1 binding
(74). This effect allows HSV-1 to prevent necrosome formation. Recently an
additional mechanism of necroptosis inhibition by HSV-1 ICP6 via the RHIM
domain was discovered. Wild type HSV-1 inhibited translocation of necrosomes to
detergent-resistant membranes as compared with HSV-1 lacking ICP6 (DICP6) or
having and ICP6 lacking the RHIM domain (ICP6-DRHIM) (75). Collectively,
these data show numerous strategies exploited by HSV-1 to prolong cell survival by
targeting RIPK1. Furthermore, these studies may shed light on similar mechanisms
shared by other viruses.

1.2 Cytomegalovirus (CMV)
The infection of mice with Murine cytomegalovirus (MCMV) is a wellestablished model for understanding human CMV infections (76). MCMV M45, the
homolog of HCMV UL45, has emerged as a viral inhibitor of RIPK1-mediated
signaling. Mutational studies done on M45 have revealed a RHIM-like domain in
the N-terminus of MCMV M45 (aa 61-69). Overexpressed WT (wild type) but not
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∆RHIM M45 co-immunoprecipitated with RIPK1 indicating that M45 interacts with
RIPK1 via its RHIM domain (77). This strong interaction between RIPK1 and M45
resulted in blocking of RIPK1 ubiquitination as shown by in vitro ubiquitination
assays

(19).

TNF⍺-induced

NF-𝛋B

activation

and

TNF⍺-induced

p38

phosphorylation were inhibited as a result of the RIPK1-M45 interaction (78). NF𝛋B activation downstream of TLR3 was also blocked by M45. Furthermore, M45
blocked caspase-independent cell death following TNF⍺ stimulation in a RHIMdependent manner. Similarly, MCMV expressing WT M45 but not ∆RHIM M45
blocked TRIF-induced apoptosis by blocking the RIPK1-TRIF interaction (77).
Interestingly, another study found an additional mechanism of RIPK1 degradation
by M45. Muscolino et al. showed that M45 physically interacted with RIPK1 via its
IPAM motif and caused RIPK1 to aggregate (73). This interaction caused RIPK1 to
accumulate in the insoluble fraction of cell lysates following MCMV infection in an
M45-dependent manner. RIPK1 levels were higher in autophagy-deficient ATG5-/cells following MCMV infection, indicating that RIPK1 was subjected to
degradation by autophagy. Further studies revealed that M45 promoted RIPK1
degradation which was blocked by inhibition of lysosome function by NH4Cl (73).
In agreement with previous studies, the authors also detected inhibition of
necroptosis due to low levels of RIPK1. Both IPAM and RHIM sequences were
needed for cell survival suggesting that these two sequences have independent roles.
Infections with MCMV expressing ∆IPAM or ∆RHIM M45 resulted in less viral
replication in mice relative to infections with WT MCMV. Therefore, M45
promoted viral replication in cell culture and facilitated viral replication in mice by
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inhibiting RIPK1-mediated cell death. RIPK3 also harbors a RHIM domain and
drives signaling for necroptosis. Thus, M45 RHIM-mediated interactions could
negatively affect RIPK3 signaling as well. Further efforts should be made to
understand if M45 can regulate RIPK3 signaling. Moreover, how RIPK1
overexpression affects viral replication could be explored.

1.3 Epstein-Barr virus (EBV)
EBV is known to manipulate the host cell’s death signaling pathways to
facilitate viral replication. EBV suppressed necroptosis by targeting RIPK1 (79).
Latent membrane protein 1 (LMP1) of EBV directly interacted with RIPK1 in an
RHIM-independent manner. Furthermore, both K48 and K63 ubiquitination of
RIPK1 increased in the presence of LMP1 as shown by in vitro ubiquitination
assays. K48 ubiquitination resulted in a decrease of the RIPK1 half-life. LMP1
increased the expression of TRAF2, which amplified RIPK1 K63 ubiquitination.
Therefore, LMP1 inhibited TNFR1-stimulated necroptosis by redirecting RIPK1
signaling towards NF-𝛋B activation by promoting K-63 ubiquitination. However,
LMP1 is also known to upregulate TNFAIP3/A20 (TNFa-induced protein 3), which
could deubiquitinate RIPK1 (80,81). Therefore, studies on the direct effect of low
levels of RIPK1 and LMP1-RIPK1 interaction on EBV replication and cell death
could be beneficial.
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2. Flaviviruses
Flaviviruses are single-stranded positive-sense RNA viruses, having a
genome size of ~11kb. Flaviviruses are mainly transmitted to vertebrate hosts by
infected mosquitos or ticks. Mosquito-borne flaviviruses include Yellow fever virus,
Dengue virus, Japanese encephalitis virus, West Nile virus and Zika virus. Tick-borne
viruses include Tick-borne encephalitis virus, Powassan virus, Louping ill virus, and
Omsk hemorrhagic fever virus (82). Ongoing research on understanding humanflavivirus interactions has exposed a protective role of RIPK1 for the host. Some
flaviviruses have evolved strategies to target RIPK1 in order to evade host responses
while these mechanisms remain to be elucidated for other flaviviruses. WNV is an
encephalitic virus of global concern (83). In humans, ~20% of WNV infections cause
rashes, arthralgia and myalgia while <1% of infections cause cognitive and
neurological impairments that can lead to death (84). ZIKV is an emerging flavivirus
which is associated with fetal abnormalities and severe neurological injuries in adults
(85,86).

2.1. West Nile virus (WNV)
RIPK1 together with RIPK3 signals for chemokine expression and for
recruitment of infiltrating antiviral leukocytes in the central nervous system during
WNV infection. Mice expressing a kinase dead form of RIPK1 exhibited increased
susceptibility to WNV infection (87). Even though the molecular mechanisms for this
effect are not completely understood, these data suggest a protective role of RIPK1
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against WNV (87). Additionally, the levels of RIPK1 upon WNV infection could be
monitored to learn if WNV impede RIPK1 mediated signaling.

2.2 Zika virus (ZIKV)
The fate of RIPK1 in ZIKV-infected cells has not been directly addressed.
However, a protective role of RIPK1 against ZIKV was recently reported. RIPK1
together with RIPK3 diminished ZIKV infection by activating antiviral gene
networks including IRF1-dependent Irg1 expression (88). The full nature of this
mechanism remains to be elucidated. However, RIPK1 kinase activity-deficient mice
(RIPK1KD/KD) had higher viral titers in whole brain homogenates upon infection with
ZIKV. Inhibition of kinase activity in vivo by treatment with pharmacological
inhibitors also increased brain viral burden. Furthermore, RIPK1KD/KD neuronal
cultures exhibited enhanced replication of ZIKV relative to wild-type controls.
Interestingly, no differences were observed in ZIKV replication in primary BMDM
or dendritic cells from wild-type versus RIPK1KD/KD mice or with inhibition of the
kinase activity of RIPK1, suggesting that these effects are cell-type specific (88).

3. Retroviruses
Retroviruses are enveloped RNA viruses (89). Retroviruses are able to reverse
transcribe their RNA genomes into DNA that integrates into the host cell genome
during the intracellular virus life cycle. It is estimated approximately 8% of the human
genome consists of endogenous retroviruses (90). Retroviruses are further categorized
into oncoretroviruses, lentiviruses and spumaviruses (91). Human Immunodeficiency
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Virus 1 (HIV-1) is a lentivirus while Human T-Cell Lymphotropic Virus-1 (HTLV-1) is
an oncoretrovirus. HIV-1 causes acquired immunodeficiency syndrome (AIDS).
Approximately 37 million people were living with HIV-1 worldwide as of 2017 (92).
Infection of T-lymphocytes by HTLV-1 can cause adult T-cell leukemia (ATL) or
HTLV-1 associated myelopathy (HAM) (93,94). Both HIV-1 and HTLV-1 have been
shown to modulate RIPK1 signaling.

3.1 Human Immunodeficiency Virus 1(HIV-1)
The HIV-1 protease (PR) plays an important role in the virus life cycle by
cleaving viral poly-peptides Gag and Gag-Pol into mature proteins (95). One study
examined the effect of HIV-PR expression on RIPK1-mediated signaling (96) HIV-1
PR was shown to decrease both endogenous and overexpressed RIPK1. A catalytically
inactive PR and the PR inhibitor Saquinavir (SQV) prevented this cleavage. Mass
spectroscopy studies revealed that PR cleaves RIPK1 at the ID domain. RIPK1
cleavage was confirmed in HIV-1-infected T cell lines and primary CD4+ T cells. PR
cleavage of RIPK1 disrupted NF-𝛋B activation as measured by luciferase reporter
assays, and this activation was restored by the addition of SQV. Furthermore, PR
overexpression impaired RIPK1-RIPK3 interaction as demonstrated by a yeast twohybrid system. These data suggest that RIPK1 cleavage by PR can block necrosome
formation inhibiting necroptosis. However, this study did not assess the effect of PR
on RIPK1-mediated MAPK pathway activation. Collectively these data indicate that
HIV-1 PR can block multiple immune pathways by cleaving RIPK1. However, the
effect of RIPK1 cleavage on HIV-1 replication remains to be studied.
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3.2 Human T-Cell Lymphotropic Virus -1
The HTLV-1-encoded Tax protein is a multifunctional protein that is crucial
for T cell transformation by HTLV-1 (97). Moreover, Tax inhibits innate immune
signaling by multiple mechanisms via RIPK1. Type I IFNs and ISGs are capable of
inhibiting HTLV-1 replication. Therefore, viral evasion of IFN production and
signaling probably represents a survival strategy. More progeny viruses were
recovered following VSV infection in primary MEF and Jurkat cells overexpressing
Tax protein relative to controls, demonstrating inhibition of host immune responses by
Tax (36). HTLV-1-infected cells produced less IFNβ than uninfected cells upon
stimulation with poly(I:C). Yeast two hybrid screens and mutational constructs
revealed a Tax interaction with RIPK1 via the RHIM in the ID domain of RIPK1(36).
However, they did not test for the presence of a RHIM domain in Tax protein. The
Tax-RIPK1 interaction prevented the RIPK1-IRF7 interaction and inhibited IRF7
phosphorylation, downregulating the production of IFN⍺ and IFNβ. In contrast, Tax
did not prevent RIPK1-RIG-I/MDA-5 interactions, and NF-𝛋B signaling was
unaffected as shown by luciferase assays (36). HTLV-1 is known to induce persistent
activation of NF-𝛋B, which contributes to the T-cell transformation (98). It was shown
that Tax prevented TLR3-induced IRF3 phosphorylation but not NF-𝛋B signaling by
competitively binding to TRIF. However, this observation is inconsistent, since TRIF
is located upstream of both IRF3 and NF-𝛋B pathways. Therefore, it is reasonable to
hypothesize Tax might be inhibiting IFR3 phosphorylation at an additional step in
TLR3 signaling.
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4. Other viruses

4.1 Human Rhinovirus (HRV)
HRV is the major causative agent of the common cold and asthma
exacerbations (99). There are approximately 170 serologically distinct HRV types in
circulation (100). HRV is a single-stranded positive-sense RNA virus. The HRV
genome encodes for three proteases (2A, 3CD, 3C), which are important for viral
polyprotein maturation (101). These proteases have also been shown to cleave host
proteins. The HRV16 3C protease restricted host cell apoptosis and prolonged cell
survival by cleaving RIPK1 in HeLa cells (102). The addition of a 3C protease
inhibitor, Rupintrivir, decreased RIPK1 cleavage. 3C-mediated RIPK1 cleavage was
increased upon caspase 8 activation by ActoD relative to untreated cells. However,
this observation of increased RIPK1 cleavage with activation of Caspase 8 was not
reproduced in HRV16-infected cells. Even though apoptosis induced with ActoD
treatment decreased upon HRV16 infection, no evidence was shown this was related
to RIPK1 cleavage. Additional studies may require for elucidating the direct effect of
RIPK1 cleavage on cell death as well as HRV16 replication. Finally, given that the
level of full-length RIPK1 is decreased during HRV16 infection, it would be
interesting to learn if RIPK1-mediated innate immune signaling such as NF-𝛋B and
MAPK pathways are disrupted. Therefore, there is an opening to investigate the
inhibition of RIPK1-mediated immune responses by HRV.
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4.2 Ebola virus (EBOV)
EBOV is a negative-strand RNA virus belonging to the Filoviridae family
(103). Ebola virus causes Ebola Virus Disease, a hemorrhagic fever with a high
fatality rate. Damaging host immune responses due to robust EBOV replication
contributes to the disease severity. This excessive viral replication reflects the
capability of EBOV to suppress innate immune mechanisms. For example, EBOV
effectively blocks IFN production (104,105). EBOV has been shown to disrupt
RIPK1-mediated signaling by encoding a miRNA (miR-T2-3p) targeting RIPK1
(106). In vitro experimental studies in HeLa cells demonstrated that a mimic of
miRNA miR-T2-3p downregulated RIPK1 transcript levels. In light of this
observation, it is tempting to hypothesize that EBOV-encoded miRNA blocks RIPK1mediated innate immune responses to enhance viral replication. Perhaps RIPK1
inhibition could be responsible for inhibition of IFN production by EBOV. Thus, it
will be of interest to study the link between RIPK1 downregulation and IFN inhibition
during EBOV infection. Also, the effect of RIPK1 inhibition on EBOV replication
could be further explored.

4.3 Vaccinia virus (VACV)
VACV belongs to the poxvirus family. It has a large linear ds DNA genome.
VACV is the primary component of the smallpox vaccine. VACV is mostly used as a
tool in the research setting for vaccine development (107). RIPK1 has been shown to
play a protective role in VACV infection by inducing necroptosis. Caspase 8
inhibition by VACV also promotes necroptosis in infected cells (108). Mice
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expressing a kinase inactive RIPK1 mutant failed to control VACV replication in vivo.
They had increased viral titers in the spleen and the liver, due to lack of necroptosis
(109). This study provides genetic evidence that the kinase activity of RIPK1 is
essential for viral-initiated necroptosis. However, further efforts should be made to
understand RIPK-mediated NF-kB, MAPK activation and cytokine production during
VACV infection.

Figure 3. Viral proteins involved in modulating RIPK1 signaling. HIV-1 PR,
CMV M45 proteins block NF-kB activation. CMV M45 blocks MAPK activation and
downstream signaling. HTLV-1 Tax protein blocks IRF3/IRF7 by binding to RIPK1.
HSV-1 ICP6, HIV-1 PR, CMV M45, EBV LMP1 all are shown to block necroptosis
by targeting RIPK1. HRV 3C protease is shown to block extrinsic apoptosis by
cleaving RIPK1.
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Concluding remarks
As discussed in this review, RIPK1 plays a crucial role in cell death and
inflammatory responses. RIPK1 is placed at an intersection of multiple pathways of
signal transduction initiated from death receptors and pattern recognition receptors.
Signaling initiated from these receptors is important for the induction of immune
responses. Importantly, new properties of RIPK1 signaling are emerging. For example,
it was previously reported that RIPK1 was not involved in TRIF-mediated IRF3/IRF7
signaling. In contrast, Hyun. J. et al., suggest a role of RIPK1 phosphorylating IRF3
downstream of TLR3 and TRIF (36). Additionally, it has been long postulated that the
kinase activity of RIPK1 is dispensable for NF-𝛋B activation (110). Nevertheless, a
RIPK1 kinase activity-dependent mechanism of NF-𝛋B activation and induction of
inflammatory responses due to TLR4 stimulation was recently reported (33). RIPK1 is
involved in driving signaling for extrinsic apoptosis in response to TNFa stimulation.
However, RIPK1 was also reported to be implicated in protecting TNFa stimulated
cell death in hepatocytes suggesting opposing roles of RIPK1 in the same pathway
(114). Furthermore, RIPK1 was shown to induce antiviral gene networks by undefined
mechanisms (88).
Evidence demonstrating that RIPK1 is involved in suppressing cell death and
inflammation while also promoting the same supports RIPK1 as a critical regulator in
cell death and inflammation signaling network. Under normal conditions, RIPK1
regulation of cell death and inflammation seem to be tightly regulated to allow
homeostasis. However, in the setting of viral infection, this homeostasis appears to be
disturbed. In most viral infections, RIPK1-mediated signaling protects the host by

49

either inducing cell death or inflammatory cytokine, IFN secretion. For example,
RIPK1 kinase activity-deficient mice had higher viral titers than wild-type mice
following ZIKV and VACV infections, and these mice showed increased susceptibility
to WNV infection (88,109,111). If the overall effect of RIPK1 is to inhibit infection,
RIPK1 becomes an attractive target for inhibition by viruses, especially due to the fact
that many signaling pathways can be blocked simultaneously. It is surprising yet
fascinating to observe the wide spectrum of mechanisms utilized by viruses to inhibit
RIPK1. As shown in Fig 3, numerous viral proteins are implicated in RIPK1-mediated
signaling. Additionally, understanding viral strategies used for evasion of RIPK1
signaling has revealed the multifunctionality of viral proteins. This is exemplified by
the identification of distinct motifs such as RHIM and IPAM domains in viral proteins.
For example, the IPAM motif is present in more than 70 viral R1 homologs of
herpesviruses and baculoviruses suggesting that its function of inducing protein
aggregation might be widely conserved (73). Understanding viral strategies of RIPK1
inhibition could potentially point towards unexplored viral-host interactions. Seeing
such a variety of strategies evolved in viruses indicates the possibility that RIPK1
inhibition is more important for viral survival than has been known.
Since RIPK1 controls the outcome of many signaling pathways, the sum of the
diverse functions attributable to RIPK1 may cooperatively contribute to the outcome.
Therefore, it may be helpful to investigate the outcome of all the possible arms of
innate immune responses controlled by RIPK1 during pathogen invasions. In
particular, how the outcome of RIPK1 signaling affects viral replication could be
studied. Physiologic extracellular signals that initiate RIPK1-mediated signaling could
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differ between in vivo and in vitro experimental models. For example, extracellular
pH, oxidants, and Ca2+ are known to trigger necroptosis (112). Therefore, distinct
outcomes due to RIPK1 inhibition between these experimental models could be
different. For example, even though RIPK1 kinase-deficient mice exhibited high viral
titers following ZIKV infections, similar results were not observed in BMDM s or
DCs after infecting with ZIKV (88).
How RIPK1 inhibition might benefit the virus over the host should also be more
fully addressed. For example, necroptosis and inflammatory signaling regulated by
RIPK1 may control viral replication but could be deleterious to the host and contribute
to disease pathogenesis. For example, necroptosis following IAV infection has been
speculated to contribute to pulmonary tissue damage and acute respiratory distress
syndrome (ARDS) (113). At this point, however, there is still a limited understanding
of specific effects of RIPK1 inhibition in disease pathogenesis during viral infections.
Overall, in this review, we discussed various strategies exploited by viruses to
inhibit RIPK1-mediated signaling. Viral modulation of RIPK1-mediated signaling
may lead to inhibition of NF-𝛋 B responses, MAPK signaling, IFN induction and cell
death mechanisms. It is likely that most viruses benefit by inhibiting these pathways
because in vivo viral replication increases by RIPK1 inhibition. Understanding the
impact of inhibition of RIPK1 signaling on the host and the virus may facilitate the
development of the next generation of immunotherapeutic strategies against virus
infections.
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Abstract
Dengue virus (DENV) infection is the most prevalent arthropod-borne virus
disease which is endemic in more than 100 countries. Several DENV proteins have
been shown to target crucial host proteins to evade innate immune responses in order
to establish a productive infection in humans. Here we report that the DENV protease,
NS3, targets RIPK1 (Receptor Interacting Protein Kinase I), a central mediator of
inflammation and cell death, and decreases intracellular protein levels during DENV
infection. Furthermore, the decrease in RIPK1 protein results in the inhibition of
TNFR- and TLR3-induced NF-𝛋B activation. Our data demonstrate a novel
mechanism by which DENV suppresses normal cellular functions to evade host innate
immune responses. This perturbation may benefit DENV and contribute to the disease
pathogenesis.

Author summary
Dengue virus infections are a major global health concern and approximately 3
billion people are at risk of infection. Dengue virus is able to establish successful
infections in humans by evading host innate immune mechanisms. Understanding
these evasion strategies would be helpful for designing effective therapeutics against
dengue infection and disease. Here we report a novel target of Dengue virus, RIPK1.
Dengue viral protease interacted with and decreased levels of RIPK1, disrupting the
NF-𝛋B signaling pathway involved in multiple innate immune responses. Our study
provides new insights into critical host – pathogen interactions of an emerging viral
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pathogen.

Introduction
Dengue is the most prevalent arthropod-borne viral disease, with an estimated
400 million infections occurring annually (1). Infected individuals may develop severe
symptoms leading to dengue hemorrhagic fever (DHF), dengue shock syndrome
(DSS), and even death. The causative agent of dengue, dengue virus , is known to
infect dendritic cells, macrophages, monocytes, B cells, T cells, hepatocytes, epithelial
and endothelial cells (2–4). The magnitude of DENV replication and its regulation of
immune responses contribute to the disease pathogenesis. Effective antiviral drugs and
vaccines are not available to treat the dengue disease, which emphasizes the
importance of understanding DENV-host interactions (5). DENV refers to a group of
four closely related positive-sense, single-stranded RNA viruses or serotypes (DENV
1, 2, 3, 4), belonging to the Flaviviridae family. Upon entry into the host cell, the
released viral genome is translated into one polypeptide, which gets cleaved into
individual structural (capsid, PrM, and envelope) and non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5) by the viral protease complex, NS2B3, and
host proteases (6). The individual DENV proteins generated are known to interact with
numerous host proteins and interfere with host antiviral immune responses. DENV
protease NS3 interacts with and cleaves STING and downregulates RLR (RIG-I like
receptors) signaling (7). DENV protease also cleaves the mitochondrial proteins
MFN1 and MFN2 and thereby impairs mitochondrial dynamics as well as efficient
RLR signaling (8).
RIPK1 has emerged as an important regulator that controls multiple cellular
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pathways involved in inflammation and cell death (9). RIPK1 is involved in innate
immune responses to bacterial and viral infections by inducing apoptosis or
necroptosis or by inducing inflammatory signaling (10). Activation of death receptors
such as TNFR1 leads to the formation of a multi-protein complex including RIPK1,
complex I, which facilitates the activation of NF-𝛋B and MAPK pathways to promote
cell survival by inducing anti-apoptotic gene expression and the induction of
proinflammatory cytokine gene expression (11). The scaffolding function of RIPK1 is
critical for NF-𝛋B activation. RIPK1 is also involved in mediating TRIF-dependent
TLR3- and TLR4-induced NF-𝛋B activation (12,13). RIPK1 can drive extrinsic
apoptosis by activating caspase-8 via the formation of a distinct multi-protein
complex, complex IIa (14), and can drive signaling to necroptosis through formation
of a complex with RIPK3 (complex IIb) (15,16). RIPK1 also has been shown to
regulate IRF3 transcription downstream of RIG-I/ MDA-5 complexes in response to
RNA viruses (17). These pathways are crucial for mounting innate immune responses
during viral infections. This central role of RIPK1 makes it an ideal target for
inhibition by viruses, as has been shown for HIV-1 (18), human Rhinovirus 3C (19),
and Epstein-Barr virus (20). However, no association between RIPK1 and DENV
infection has been reported to date. Therefore, the objective of this study was to
evaluate the effect of DENV infection on RIPK1 signaling. We show that RIPK1 is
targeted by DENV protease NS3, which results in decreased RIPK1 protein levels
during DENV infection. Consequently, TNFa- and poly (I:C)- induced NF-𝛋B
activation is impaired during DENV infection which may benefit viral replication.

66

Results
RIPK1 protein levels decrease with DENV infection
DENV is known to infect hepatocytes and the liver is one of the major organs
affected during DHF (21). We tested the effect of DENV infection on the human
hepatoma cell line, Huh7. A time-course analysis of DENV2 infection revealed a
reduction in intracellular RIPK1 protein concomitant with the expression of DENV
NS3 as early as 6h post-infection (Fig 1A). In order to see if this was a general effect,
we infected cell lines originated from different human tissues with DENV2 as well as
monocyte-derived dendritic cells (MoDC), which is a relevant primary cell system
(22). We observed a significant decrease in endogenous RIPK1 protein levels with
DENV2 infection in all the cells tested (Fig 1B). Overexpressed Flag-tagged RIPK1
was also decreased in a dose-response manner in DENV2-infected HEK 293T cells
(Fig 1C). This effect was specific for RIPK1 since endogenous or overexpressed
RIPK3 levels were not affected by DENV infection (Fig 1D). Different strains of
DENV1 and DENV2 decreased RIPK1 significantly in Huh7 cells; however, no
significant decrease was observed in cells infected with several strains of DENV3 or
DENV4 (Fig 1E & F).
Next, we investigated if DENV inhibited RIPK1 at a transcriptional level. A
time-course study was done with DENV2 infection in Huh7 cells. We did not see a
decrease in RIPK1 transcript levels, indicating that the downregulation of RIPK1
occurred at the post-transcriptional level (Fig 1G & H).
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RIPK1 is reduced by DENV protease
Negative regulation of RIPK1 by caspase 8 is well known. During activation of
death receptors, active caspase 8 cleaves RIPK1 in the intermediate domain at Asp 324
(23). Therefore, we first tested if active caspase 8 plays a role in decreasing RIPK1
levels during DENV infection. Caspase 8 inhibition by zVAD-FMK was not sufficient
to restore the decreased RIPK1 levels during DENV infection (S1). These data suggest
that the decrease in RIPK1 in DENV-infected cells is not a result of cleavage by
caspase 8.
RIPK1 is known to be targeted by several viral proteases to counteract its
functions and enhance viral replication (18,19). Therefore, to evaluate the mechanism
of RIPK1 reduction during DENV infection, we tested whether expression of the
DENV NS2B3 protease complex was sufficient to reduce RIPK1 levels. We cotransfected a Flag-tagged RIPK1 and a plasmid encoding DENV NS2B3. We observed
a dose response in RIPK1 reduction with the expression of DENV NS2B3 (Fig 2A,
2B). However, we did not detect the accumulation of a cleaved product of RIPK1
using antibodies targeting either the C-terminal or N-terminal segment of RIPK1. In
order to determine if the protease activity was important for this effect, we created a
catalytically inactive protease mutant, NS2B3-S135A (S2, (24)) Transfection of
NS4B5-GFP, a target of DENV protease, confirmed the lack of protease activity of the
mutant NS2B3 construct (25). Levels of neither endogenous nor overexpressed RIPK1
were affected upon transfection of NS2B3-S135A, demonstrating that protease
activity of NS2B3 was required for the reduction of RIPK1 levels (Fig 2C).
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In order to evaluate if the reduction in RIPK1 is due to a direct effect of
NS2B3 on RIPK1, we next performed co-immunoprecipitation experiments to detect a
physical interaction between RIPK1 and NS2B3. HEK 293T cells were co-transfected
with a Flag-tagged RIPK1 plasmid and a plasmid expressing either V5-tagged wild
type

(WT)

DENV

NS2B3

or

NS2B3-S135A.

DENV

NS3

protein

co-

immunoprecipitated with RIPK1 when pulled down with anti-Flag (Fig 2D, lane 3).
As expected, the reciprocal immunoprecipitation using anti-V5 antibodies confirmed
this interaction. Strikingly, a physical interaction between RIPK1 and NS2B3-S135A
was also detected using specific antibodies (Fig 2D, lane 4). This suggests that NS3
protease activity was not required for this protein-protein interaction even though it
was necessary for decreasing RIPK1 levels (Fig 2C). We then validated the interaction
of RIPK1 and NS3 in the context of DENV infection. HEK 293T cells transiently
expressing Flag-RIPK1 were infected with DENV2 for 48hrs, then RIPK1 was
immunoprecipitated using an anti-Flag antibody. We detected DENV NS3 bound to
RIPK1 by western blot analysis (Fig 2E lane 2). We performed the reciprocal
immunoprecipitation using an anti-DENV NS3 antibody and detected RIPK1 bound to
DENV-NS3 by western blot analysis, verifying the interaction (Fig 2E).

DENV impairs TNFR- and TLR3-induced NF-𝛋B activation
RIPK1 is an adapter molecule downstream of TNFR and TLRs and plays an
important role in downstream signaling leading to NF-𝛋B activation (3). Having
established that DENV NS3 decreases RIPK1, we examined whether the loss of
RIPK1 disrupts NF-𝛋B activation during DENV infection. First, in order to test how
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NF-𝛋B activation is affected downstream of TNFR, Huh7 cells were transfected with
a plasmid encoding a luciferase gene driven by NF-𝛋B response elements and a
plasmid expressing Renilla luciferase as a control. Cells were stimulated with TNFɑ
either prior to or after DENV infection. Cells were cultured for 48hrs post-infection
and the luciferase activity was measured as described in Methods. NF-𝛋B activation in
response to TNFɑ was significantly attenuated in DENV-infected cells as compared to
uninfected cells when TNFɑ was added either before or after infection (Fig. 3A). We
then assessed NF-𝛋B luciferase activity in response to TNFɑ stimulation with
overexpression of RIPK1 in HEK 293T cells. NF-𝛋B luciferase activity was
significantly reduced with DENV infection but this was restored by overexpression of
RIPK1 (Fig 3B).
We then examined the effect of DENV infection on NF-𝛋B activation in
response to TLR3 stimulation. HEK 293T cells stably expressing TLR3 were
transfected with the luciferase reporter plasmids with or without the Flag-RIPK1
plasmid and then infected with DENV (MOI=3). They were further stimulated with
poly I:C for 24hrs and luciferase activity was measured. DENV infection impaired
poly I:C-induced NF-𝛋B activation relative to uninfected cells (Fig 3C).
Overexpression of RIPK1 increased NF-𝛋B activity in both uninfected and DENVinfected cells. However, even with RIPK1 overexpression, there was a significant
decrease in NF-𝛋B activity in the presence of DENV relative to uninfected cells (Fig
3C). These results demonstrate that DENV infection impairs NF-𝛋B activation
downstream of both TNFR and TLR3 by decreasing RIPK1 protein levels.
We further investigated if DENV NS2B3 downregulated NF-𝛋B activation by
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targeting RIPK1. NF-𝛋B luciferase assays were performed with co-transfection of
Flag-RIPK1 and WT NS2B3 or NS2B3-S135A. Increased NF-𝛋B activity due to
overexpression of RIPK1 was attenuated by expression of WT NS2B3 but not by
NS2B3-S135A (Fig 3D). These data indicate that expression of DENV NS2B3 is
sufficient to inhibit NF-𝛋B activation by RIPK1, but that the physical interaction
between NS2B3 and RIPK1 is insufficient for this effect.
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Figure 1. Endogenous and overexpressed RIPK1 decreases during DENV
infection. (A) Time course study of DENV2 infection in human Huh7 cells with MOI
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of 1 and 3 for the indicated hrs. Cell lysates were harvested for western blot analysis
using the indicated antibodies. (B) Western blot analysis of RIPK1 in indicated cells
infected with DENV2 (MOI=2) and cultured for 48hrs. 𝛃-actin was used as a loading
control. (C) Western blot analysis of overexpressed RIPK1 and (D) RIPK3 followed
by DENV2 infection in HEK 293T cells at 48h post-infection. (E) Western blot
analysis of Huh7 cells infected with different DENV strains for 48 or 72 hrs and
probed with antibodies to RIPK1 and DENV NS3. (F) RIPK1 band intensities at 72hrs
p.i. were normalized to 𝛃-actin and were quantified by Image Lab software from 3
independent experiments. Data are mean ± SD and were compared by Student’s t test
(GraphPad Prism 8). (G) RT-qPCR analysis of total RNA isolated from Huh7 cells
infected with DENV2 (MOI=2) for (G) RIPK1or (H) intracellular DENV RNA for the
indicated time points. Data are mean ± SD (n=2 experiments) and were compared by
Student’s t test (GraphPad Prism 8). Western blots are representative data from a
minimum of 3 independent experiments (panels A-E).
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Figure 2. DENV NS3 protease interacts with and decreases RIPK1. (A) Western
blot analysis of HEK 293T cells co-transfected with Flag-RIPK1 and increasing
concentrations of a plasmid expressing the DENV NS2B3 protease complex. (B)
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Densitometric analysis of RIPK1 band intensities normalized to β-actin levels. Results
are from a single experiment and are representative of at least three separate
experiments. (C) Western blot analysis of HEK 293T cells co-transfected with FlagRIPK1 and plasmids expressing either WT NS2B3, NS2B3-S135A or an empty vector
(pcDNA) and cultured for the indicated times. (D) Co-immunoprecipitation analyses
of HEK 293T cells transiently overexpressing Flag-RIPK1 and WT NS2B3 or NS2B3S135A DENV protease complexes. (E) Co-immunoprecipitation analyses of HEK
293T cells transfected with Flag-RIPK1 and mock (media) or DENV (MOI=1)
infected for 48hrs. IP = immunoprecipitation, IB = immunoblot.
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Figure 3. TNFα- and poly(I:C)-driven NF-𝛋B activation is impaired during
DENV infection. (A) NF-𝛋B luciferase activity was assessed in Huh7 cells cotransfected with a NF-𝛋B luciferase reporter and a control Renilla luciferase reporter
plasmid and stimulated with hTNFα (50ng/ml) before or after DENV2 infection and
cultured for 48hrs (B) HEK 293T cells were co-transfected with NF-𝛋B luciferase
reporter, Renilla luciferase reporter and Flag-RIPK1 followed by DENV2 infection
(MOI=3). Following TNFα (50ng/ml) treatment for 24hrs, cells were lysed, and
luciferase activity was measured at 72hrs post-infection. (C) NF-𝛋B luciferase activity
was assessed in HEK 293T-TLR3 cells as in (D) and cells were stimulated with poly
(I:C) 20µg/ml for 24hrs before cell lysis. (D) HEK 293T cells were co-transfected
with NF-𝛋B luciferase reporter, Renilla luciferase reporter, and Flag-RIPK1 along
with WT DENV NS2B3 or NS2B3-S135A. Luciferase activity was detected at 48hrs
post-transfection. Results are representative of at least three independent experiments
and are expressed as mean ± SD from three biological replicates. (One-way ANOVA,
P < 0.0001)
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Supporting information
Figure S1. Caspase 8 does not contribute to RIPK1 decrease in DENV infection.
Western blot analysis of RIPK1 levels in HUH7 cells with inhibition of caspase
activity by zVAD-FMK or treated with DMSO or Staurosporine following 42hrs of
DENV2 infection.

Figure S2. DENV NS2B3-S135A lacks protease activity. Western blot analysis of
HEK 293T cells transfected with WT NS2B3 or NS2B3-S135A along with a substrate
(NS4B5) for protease activity. Cell lysates were harvested 48hrs post-transfection and
protein expression was analyzed by anti DENV NS3 or anti DENV NS4B.
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Discussion
RIPK1 is a critical regulator of cell death and inflammation, and acts as an
important adapter protein downstream of several receptors including TNFR, TLR3,
TLR4, and RIG-I (26). Recently an anti-viral role of RIPK1 has emerged as it is
involved in modulating an inflammatory form of cell death, necroptosis, and is also
implicated in modulating NF-𝛋B and IFN responses (17,27,28). Therefore, we
investigated the role of RIPK1 in DENV infection. We observed a pronounced
reduction of RIPK1 during DENV infection in multiple cell types, including primary
monocyte-derived dendritic cells. This effect could be reproduced by expression of the
functionally active DENV protease, NS3. Furthermore, we demonstrated an inhibitory
effect of DENV infection on NF-𝛋B activation in response to TNFɑ and poly I:C by
targeting RIPK1.
DENV is known to target host proteins to evade host innate immune responses.
DENV NS5 protein is involved in degrading STAT2 to interfere with IFN responses
(29). DENV protease complex NS2B3 interacts with and cleaves STING and
downregulates the RLR pathway (7). DENV protease is also involved in cleaving
mitochondrial proteins MFN1 and MFN2 and thereby impairs mitochondrial dynamics
as well as efficient RLR signaling (8). Previous findings also show that protease
cofactor NS2B interacts with cGAS and promotes it for autophagosome-mediated
degradation (30). These strategies serve to enhance viral replication.
Our findings add RIPK1 to the list of host proteins targeted by the DENV
protease. Targeting of RIPK1 has the potential to give an added advantage to the virus
since RIPK1 mediates several crucial signaling pathways. RIPK1 has an N terminal
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kinase domain, a RHIM (RIP homotypic interaction motif) containing intermediate
domain, and a C terminal death domain (DD). RIPK1 binds to the DD of FADD,
TNFR1, TRADD (31–33). The RHIM domain of RIPK1 mediates interactions with
other RHIM containing proteins such as RIPK3, TRIF, and ZBP1 (13,34,35). Here, we
observed a physical interaction between RIPK1 and DENV NS3. There may be other
proteins involved in this NS3-RIPK1 complex. The domains and motifs of DENV
NS3 and RIPK1 important for this interaction have to be determined. There have been
a few published studies and databases on DENV-human protein-protein interactions
(36,37), but none reported RIPK1 as a target of DENV protease, NS3. This could be
due to the fact that endogenous RIPK1 remains undetected for Mass Spectrometry due
to the significant reduction in protein levels by DENV.
Caspase 8 is known to negatively regulate RIPK1 by cleaving it following the
induction of extrinsic apoptosis (23). However, decreased RIPK1 levels were seen
during DENV infection even with inhibition of caspase 8 (S1). Furthermore, RIPK1
was not inhibited at the transcriptional level by DENV (Fig 1H). Interestingly, the
catalytic activity of NS2B3 was important for RIPK1 reduction since catalytically
inactive mutant NS2B3-S135A did not decrease RIPK1 efficiently. However, we were
not able to detect a cleaved/degraded product of RIPK1 using either C-terminal or Nterminal targeting antibodies. These data suggest that the product of cleavage by
NS2B3 is too small to detect or could have been further degraded rapidly by other
cellular mechanisms such as proteasome-mediated or lysosome-mediated degradation.
Nevertheless, we hypothesize that NS2B3 plays a direct role in decreasing RIPK1
levels based on the evidence of a physical interaction of DENV NS3 and RIPK1. The
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NS2B3-S135A mutant also interacted with RIPK1 demonstrating that the catalytic site
is not required for this interaction. Similarly, both the active and inactive NS2B3
interacted with STING but only the active protease was able to effectively decrease its
levels (7).
Increased serum TNFɑ levels have been reported in patients with dengue (38).
The interaction of TNFɑ and TNFR1 results in the formation of complex I leading to
NF-𝛋B activation (39). NF-𝛋B transcription factors regulate a large number of genes
involved in immune responses. Therefore, signaling leading to NF-𝛋B activation
serves as an anti-viral immune mechanism. Viruses inhibit NF-𝛋B pathway activation
to evade these host immune and inflammatory responses (40). DENV infection was
shown to block NF-𝛋B activation downstream of TLR signaling resulting in
downregulated cytokine production (41). Similar studies in Huh7 and monocytederived macrophages showed that DENV infection altered cellular responses to TNFɑ
stimulation (42). However, the mechanism by which DENV caused these altered
responses had not been defined. We demonstrated that DENV infection diminished
NF-𝛋B activation in response to TNFɑ or poly I:C stimulation and that NF-𝛋B
promoter activity drastically increased when RIPK1 was overexpressed both in the
presence and the absence of DENV infection. We also demonstrated that increased
NF-𝛋B luciferase activity in response to the over-expression of RIPK1 was
significantly decreased with the over-expression of WT NS2B3 but not with NS2B3S135A. Together these results show that the levels of RIPK1 are critical for regulating
upstream signals leading to NF-𝛋B activation and that DENV infection dampens NF𝛋B transcription by targeting RIPK1.
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Liver injury is a common finding in DENV infection and can lead to organ failure.
Apoptosis of hepatocytes following DENV infection is believed to contribute to this
phenomenon (21). Recent findings show a protective role of RIPK1 in TNFɑ-mediated
apoptosis in hepatocytes (43,44). RIPK1 knockout mice showed enhanced sensitivity
to TNFα-mediated apoptosis and inflammation. Induction of NF-𝛋B target gene
transcripts was also suppressed in these mice. Therefore, we speculate that loss of
RIPK1 during DENV infection may sensitize hepatocytes to cell death and
inflammation, which could contribute to liver injury in DHF. We observed differences
between DENV strains in their effect on RIPK1 levels. These differences could relate
to differences in protease structures and might contribute to differences in disease
manifestations but further analysis would be required to establish those associations
(45–47)
To the best of our knowledge, this is the first description of DENV targeting
RIPK1. This is also the first report of inhibition of NF-𝛋B signaling by the DENV
protease NS2B3 by targeting RIPK1. These findings open up new research directions
on the interplay of DENV with various emerging functions of RIPK1. Further studies
are required to shed light on cell- and context-dependent effects of RIPK1 reduction in
vivo during DENV infection. Finally, we believe that these data expand knowledge of
strategies used by DENV to evade innate immune responses.
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Materials and methods
Cell culture and virus infection
Huh7, HEK 293T cells stably expressing TLR3 ( generous gifts from Dr. Kate
Fitzgerald), HEK 293T (Dharmacon, Inc.) Vero, Huh 7.5 (obtained from American
Type Culture Collection (ATCC)) were maintained in Dulbecco's modified minimal
essential medium and HepG2 (ATCC) cells were maintained in Eagle's Minimum
Essential Medium, supplemented with 10% heat-inactivated fetal bovine serum
(Sigma-Aldrich), 1% penicillin-streptomycin (Sigma-Aldrich), 1% non-essential
amino acids (Lonza) and 1% L-Glutamine solution (Sigma-Aldrich). All cells were
incubated in a humidified chamber at 37 °C and 5% CO2. Prototype DENV strains
DENV1 Hawaii, DENV1 CO245/96, DENV2 16681, DENV2 New Guinea C (NGC),
DENV3 CH53489, DENV3 CO360,

DENV4 814669 and DENV4 H241 were

originally obtained from the American Type Culture Collection , the Walter Reed
Army Institute of Research or Armed Forces Research Institute for Medical Sciences
(Bangkok, Thailand), and were passaged multiple times in C6/36 cells (ATCC, USA).
Virus titers were determined by immunostained plaque assay on Vero cells (25,48).
Generation of MoDCs
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat of healthy
donors obtained from Oklahoma Blood Institute (Oklahoma City, OK) by density
gradient centrifugation on Ficoll- Paque Premium (GE Healthcare). Monocytes were
isolated from PBMCs by positive selection using CD14+ microbeads (Miltenyi
Biotec). Monocytes were cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated FBS (Sigma-Aldrich), 1% penicillin- streptomycin (Sigma-Aldrich),
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50 ng/mL human interleukin-4 (IL-4) and 160 ng/mL human granulocyte-macrophage
colony-stimulating factor (GM-CSF) for 5 days to generate monocyte-derived
dendritic cells (MoDCs). Fresh medium with cytokines was added at day 3, and cells
were infected with DENV2 at day 5.

Antibodies and reagents
The following primary antibodies were used for co-immunoprecipitation and western
blot experiments: anti-Flag-HRP (sc-166355, Santa Cruz Biotechnology), mouse antiRIPK3 (sc-374639, Santa Cruz Biotechnology), anti-β-actin-HRP (ab20272, Abcam),
anti-V5 tag (ab27671, Abcam), anti V5-HRP (R961-25, Invitrogen), anti-GAPDHHRP (MA515738) anti-DENV NS3 (GTX124252, GeneTex), anti-DENV NS4B
(GTX103349, GeneTex), anti-RIPK1 (D94C12, Cell Signaling Technology) and
mouse anti-DENV2 (MAB8702, EMD Millipore). Secondary antibodies used were
goat anti-rabbit-HRP (32260, Thermo Scientific), anti-mouse-HRP (sc516102, Santa
Cruz Biotechnology).

Caspase 8 inhibition
HUH7 cells were infected with DENV2 (MOI=1) and cultured for 48hrs. Cells were
treated with 10µM-40µM of a pan caspase inhibitor; z-VAD-FMK (SC-3067, Santa
Cruz Biotechnology) or DMSO (BP231-100, Fisher Scientific) or 1 µM of
Staurosporine (S4400, Sigma Aldrich) for 6hrs before cell lysis.
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Western Blot analysis
Cells were lysed in RIPA buffer freshly supplemented with a protease and phosphatase
inhibitor cocktail (Sigma aldrich). Lysates were incubated on ice for 30 min with
vortexing every 5 minutes and centrifuged at 10,000 rpm for 5 min at 4 °C.
Supernatants were used as total cell lysates. Protein concentrations were determined
using Pierce BCA Protein Assay kit (Thermo Fisher Scientific) following
manufacturer's instructions and measured using an Envision plate reader
(PerkinElmer). BOLT LDS Sample Buffer and Reducing Agent (Thermo Fisher
Scientific) were added to cell lysates at a final concentration of 1x and samples were
denatured at 70 °C for 10 min. Proteins were separated on 4–12% or 8% BOLT BisTris Plus gel (Thermo Fisher Scientific) and transferred onto nitrocellulose membranes
®
using the Trans-Blot TurboTM RTA Mini Nitrocellulose Transfer kit (Bio-Rad).

Membranes were blocked in 5% milk in phosphate buffered saline with 0.1% Tween
20 for 1 h at room temperature (rt) followed by incubation with the appropriate
primary antibody overnight at 4 °C. Membranes were washed and incubated with the
appropriate secondary antibody diluted in blocking buffer for 1 hour at rt. For β-actin
and GAPDH analysis, membranes were stained for 1 hour with corresponding
antibodies. Detection of blots was done using Amersham ECL Select Western Blotting
Detection Reagent (GE Healthcare Life Sciences) following the manufacturer's
guidelines and images were captured with ChemiDocTM XRS+ System (Bio-Rad).
Detection and quantification of band intensities were performed using Image Lab 5.1
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(Bio-Rad).

Co-Immunoprecipitation
Cells were lysed with RIPA buffer containing a cocktail of protease and phosphatase
inhibitors. Protein G dynabeads (Thermo Fisher Scientific) were incubated with either
mouse anti-Flag (Santa Cruz), mouse anti-V5 (abcam) or mouse anti NS3 (Genetex)
for 1 hr at rt. Then, cell lysates were incubated with antibody-coated beads overnight
at 4°C. The immunocomplex was eluted under denaturing conditions according to the
manufacturer’s recommendations, and then examined by Western blot analysis.

Plasmids, and transfections
The following plasmids were used in our study: pNS4B5-eGFP, pNS2B3-V5 (16).
pNS2B3-S135A was created by site-directed mutagenesis (Quik Change II sitedirected mutagenesis kit, Agilent Technologies) using WT NS2B3 plasmid. The
plasmid sequence was verified by DNA sequencing. Plasmids expressing Flag-RIPK1
and RIPK3-GFP were obtained from Addgene. The luciferase reporter constructs
containing a tandem repeat of the consensus binding site for the transcription factor
NF-𝛋B, and a Renilla reniformis luciferase were obtained from Strategene.
®
Transfection of cells with plasmids was performed using GeneJuice Transfection

Reagent (EMD Millipore), according to the manufacturer's instructions.

RT-qPCR analysis

87

Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen).
Quantitative RT- PCR was performed using iTaq Universal probes 1 step kit (Biorad)
or iTaq Universal SYBR Green 1 step kit (Biorad) on a Bio-Rad CFX machine, and
gene expression was normalized to β-actin expression level. Taqman gene expression
assays (RIPK1) were purchased from Thermofisher Scientific. DENV primers were
purchased from Integrated DNA Technology (IDT) and RT-qPCR was performed to
detect relative DENV RNA in cell lysates (40).

Luciferase reporter assays
HEK 293T cells were plated in 96 well plates and were co-transfected with a NF-𝛋B
luciferase reporter, a Renilla luciferase reporter and, and a plasmid encoding Flag®
tagged RIPK1 using GeneJuice Transfection Reagent (EMD Millipore), according to

the manufacturer’s protocol. Co-transfected cells were infected with DENV2 (NGC,
MOI=3) and were cultured for 72hrs and were stimulated with hTNFɑ (50ng/ml).
Luciferase activity was quantified using the dual Glo luciferase assay system
(Promega). HEK 293T cells stably expressing TLR3 were co-transfected and infected
with DENV as described above and were stimulated with poly I:C (20µg/ml) for
24hrs. At the end of the treatment, luciferase activity was measured using the dual Glo
luciferase assay system (Promega).

Statistical analysis
The statistical analyses were performed using one-way analysis of variance (ANOVA),
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with Tukey’s methods or the unpaired, two-tailed, Student’s t-test. P values were
calculated using Graphpad Prism 8 program. Differences were considered statistically
significant at P values less than 0.05.
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CHAPTER 4
Additional mechanisms and implications of RIPK1 downregulation by DENV

DENV does not mediate RIPK1 degradation via proteasomes or lysosomes

Introduction
The ubiquitin-proteasome and the autophagy-lysosome pathways are the two
major-protein degradation routes in eukaryotic cells (1). Proteasomes are barrelshaped multi protein complexes that mediate degradation of short-lived and misfolded
proteins (2). Most proteins are covalently modified with ubiquitin (Ub) before they are
targeted for proteasomal degradation. Usually, three enzymes; ubiquitin-activating
(E1), ubiquitin-conjugating (E2) and ubiquitin-ligating (E3), are involved in this
process, as shown in Fig 1 (3).

Figure 1. Schematic diagram of the ubiquitin-proteasome system. Specific
substrates and misfolded proteins are degraded by the proteasome machinery
following ubiquitination.
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There is evidence of DENV targeting the proteasome pathway to degrade key
host proteins to evade host immune responses. The reduction in STAT2 protein levels
by the DENV NS5 protein was blocked by treatment with the proteasome inhibitor,
MG-132, indicating that intact proteasome activity was required for the STAT2
reduction (4). DENV NS2B3 cleaved mitochondrial proteins MFN1 and MFN2, and
the cleaved fragments were further degraded by host proteasome machinery (5).
The degradation of cytoplasmic proteins or organelles via the lysosome is
predominantly mediated by autophagy (6). This process involves the formation of
autophagosomes/ autophagic vacuoles surrounding the proteins to be degraded (Fig 2).
These vacuoles fuse with lysosomes to form autophago-lysosomes. The interior
contents of autophago-lysosomes then get degraded by acidic lysosomal hydrolases.
The cytosolic protein LC3-II, which is derived from LC3-I, is recruited to the outer
membrane of the developing autophagosome and plays a major role in autophagosome
elongation. Therefore, LC3-I to LC3-II conversion and LC3-II degradation detected
by western blotting is used as a marker for autophagy (7). DENV has been shown to
increase protein degradation via the autophagy-lysosome pathway. DENV protease cofactor NS2B interacted with and promoted autophagosome-mediated degradation of
cGAS, which is a key component in the DNA sensing pathway (8). cGAS protein
levels in the presence of NS2B increased upon treatment with an autophagy inhibitor
(3MA) or lysosome inhibitors (Chloroquine/CLQ, NH4Cl).
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Figure 2. Schematic diagram of the autophagy-lysosome pathway with specific
inhibitors.

Upon

initiating

by

PI3K,

autophagosomes

containing

specific

molecules/proteins to be degraded fuse with lysosomes. Lysosomal enzymes then
degrade the contents in the autolysosome enabling recycling of nutrients. 3MA
specifically inhibits autophagosome formation. Chloroquine and Bafilomycin A1
inhibit autophagosome-lysosome fusion. NH4Cl alters the pH in the autolysosome
inhibiting enzymatic activation.
When RIPK1 is K48 poly-ubiquitinated by cIAP1/2 (cellular inhibitor of
apoptosis 1/2) downstream of TNFR1, it is degraded via the proteasome (9). RIPK1
can also be degraded via the lysosome by CHIP E3 ligase-mediated ubiquitylation
(10). Since we detected decreased RIPK1 levels with DENV infection, we
hypothesized DENV may promote RIPK1 degradation via proteasomal/lysosomal
degradation pathways.

Results and Discussion
In order to test if RIPK1 is degraded by proteasomal/lysosomal degradation
machinaries, Huh7 cells were infected with DENV2 (MOI=0.2 or MOI=1) for 24 hrs.
Cells were then treated with MG132, CLQ, or the vehicle control, DMSO, for 24hrs,
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and the cell lysates were analyzed by western blotting (Fig. 3). As expected, based on
the results presented in Chapter 2, RIPK1 levels significantly decreased with DENV2
infection. However, the RIPK1 levels did not recover with the inhibition of either the
proteasome or the lysosome pathways. Chloroquine treatment clearly increased the
LC3-II levels indicating efficient inhibition of lysosomal function (Fig 3 lanes 7-9).
Taken together these data suggest that RIPK1 is not subjected to these cellular
degradation machineries by DENV.
We were not able to detect a cleaved/degraded product following the DENV
NS3-dependent decrease of RIPK1 by using either an N-terminal targeting or a Cterminal targeting antibody. It is possible DENV NS3 cleaves RIPK1, which still has
to be resolved. Possibly the product of cleavage by NS2B3 is too small to detect or
could have been further degraded rapidly by other cellular mechanisms such as
proteasome-mediated or lysosome-mediated degradation. However, inhibition of the
proteasome by MG132 or Bortezomib treatment following NS2B3 overexpression did
not increase RIPK1 levels nor did it reveal smaller size bands for RIPK1 (data not
shown).
We further investigated whether RIPK1 fragment(s) might be degraded via
autophagy. In order to test this, we co-expressed RIPK1 and NS2B3 in cells cultured
in the presence or absence of the autophagosome-formation inhibitor 3MA (11).
Preliminary results demonstrated that RIPK1 levels still decreased in the presence of
DENV NS3 despite 3MA treatment (Fig 4). Taken together these data suggest that
RIPK1 was not degraded via either the proteasome or the lysosome after NS3mediated decrease. Therefore, it is possible that the resulting RIPK1 product/s from
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NS3-mediated cleavage could be too small to detect by western blotting. However,
further studies are needed to elucidate the complete mechanism. For example, 3MA
doses could be optimized and additional markers such as LC3-II levels could be used
to confirm successful autophagy inhibition.

Figure 3. RIPK1 is not degraded via proteasomes or lysosomes during DENV
infection. Huh7 cells were infected with DENV2 followed by proteasome and
lysosome inhibition using MG132 or Chloroquine (CLQ), respectively. Cell lysates
were harvested for western blot analysis using the indicated antibodies. GAPDH was
used as a loading control. Representative data are shown from a minimum of 2
experiments for each inhibitor.
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Figure 4. RIPK1 is not degraded via autophagy following NS2B3 expression.
Western blot analysis of RIPK1 levels following the inhibition of autophagy with
3MA using the indicated antibodies. Expression and efficient cleavage of NS2B3 is
detected by aNS3 antibody. β actin is used as a loading control.
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DENV suppresses TSZ-induced necroptosis
Introduction
RIPK1 is involved in inducing cell death by necroptosis downstream of
TNFR1, TLR3, and TLR4 (12). The kinase activity of RIPK1 is important for
phosphorylation of RIPK3 (13). Phosphorylated RIPK3 in turn phosphorylates
MLKL, which translocates to the plasma membrane (Fig 5). MLKL polymerizes itself
and permeabilizes the plasma membrane, releasing PAMPs and DAMPs into the
extracellular milieu. Other immune cells are then recruited to the site of necroptosis
and initiate inflammatory responses (13). Necroptosis can be blocked by the RIPK1
kinase inhibitor Necrostatin-1 (14). The most established experimental protocol for the
induction of necroptosis involves signaling through TNFR1. Treatment with TNFα,
Smac mimetic, and zVAD cocktail (T/S/Z) is known to cause necroptosis in numerous
cells (15,16). Smac mimetic antagonizes cIAP proteins and diverts TNFa signaling
from NF-kB activation (17). Pan-caspase inhibitor zVAD then diverts signaling to
induce necroptosis (18).

As RIPK3 phosphorylation at S227 and MLKL

phosphorylation at T357/S358 are critical for the this process, pRIPK3/ pMLKL are
used as markers for detecting the induction of necroptosis (19). In order to sustain cell
survival and to inhibit inflammatory responses, viruses have evolved many strategies
to counteract necroptosis. Viruses have evolved proteins that target and decrease
RIPK1 levels or block RIPKI interaction with RIPK3 by competitive binding to
RIPK1 (20,21). However, no investigations have been reported on necroptosis during
DENV infection to date.
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Figure 5. RIPK1-mediated necroptosis induction. Upon stimulation of TNFR1,
TLR3 or TLR4, RIPK1 interacts with RIPK3 and they mutually phosphorylate each
other in a complex known as the “necrosome”. Phosphorylated RIPK3 phosphorylates
MLKL. Phospho-MLKL translocates to the plasma membrane, polymerizes and
compromises plasma membrane integrity by undefined mechanisms.

Results and discussion
We have observed cell condensation and fragmentation by microscopy in many
cell lines following DENV infection, indicating cell death, especially after 24hrs.
Since RIPK1 levels significantly decreased during DENV infection we hypothesized
that necroptosis was not a major cause of DENV-induced cell death. In order to
confirm this, we compared the cell viability in different cell lines after treating with
the specific RIPK1 inhibitor, Necrostatin-1 (Nec1) or the vehicle control DMSO
followed by DENV infection. Cell viability was significantly decreased by DENV.
However, consistent with our hypothesis, Nec-1 treatment did not increase cell
survival after DENV infection (Fig 6A-E). These data suggest that necroptosis does
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not play a major role in DENV infection, perhaps to the benefit of the virus.
Next, we hypothesized DENV will suppress induced necroptosis. Since not all
cell types are sensitized to undergo T/S/Z-induced necroptosis, we first tested if
human U937 cells stably expressing DC-SIGN undergo necroptosis upon T/S/Z
treatment (16). U937-DC-SIGN cells treated with T/S/Z had less viability after 6hrs of
treatment (Fig 6F). This effect was not due to apoptosis, since cleaved caspases were
not detected (Fig 6F). We next analyzed the level of T357/S358-phosphorylated
MLKL as a marker for the induction of necroptosis. We detected a significant increase
in p-MLKL in T/S/Z-treated U937-DC-SIGN cells, confirming it’s a good model to
use for our studies (Fig 6F).
Next, to test the effect of DENV on necroptosis we treated DENV2-infected
and uninfected human U937-DC-SIGN cells with necroptosis inducers (T/S/Z) and/or
RIPK1 inhibitor Nec-1. T/S/Z induced an increase in p-MLKL in uninfected U937DC-SIGN cells which was significantly suppressed by treatment with Nec-1. In
contrast, p-MLKL was hardly detected in DENV-infected cells following T/S/Z
treatment (Fig 6G-H). Taken together, these data indicate that DENV does not signal
for necroptosis induction. Furthermore, DENV infection inhibits T/S/Z induced
necroptosis (Fig 6G-H). However, in order to confirm in vivo responses, it would be
better to investigate the effect of DENV on necroptosis induction downstream of
TLR3 and TLR4 signaling as well.
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Figure 6. DENV suppressed necroptosis. (A-E) Indicated cell lines were treated with
Nec-1 or DMSO followed by DENV2 infection for 48hrs. Cell viability was measured
by detecting ATP-producing cells with Cell Titer Glo assay. The viability of DMSOtreated uninfected cells is defined as 100%. (F) U937-DC-SIGN cell were treated with
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TSZ, TSZ + Nec-1, or DMSO treatment for 6hrs, (G) U937-DC-SIGN cells were
treated with DENV2 for 48hrs followed by TSZ, TSZ + Nec-1, or DMSO treatment
for 6hrs. Cell lysates were analyzed by western blotting using the indicated antibodies.
(H) Densitometric analysis of p-MLKL band intensities normalized to β-actin levels.
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RIPK1 expression does not affect DENV replication in vitro

Introduction
Disruption of innate immune responses may give pathogens an advantage for
establishing infection. RIPK1 is a central mediator of many cellular signaling
pathways that are important in innate immune responses. Therefore, RIPK1 is an
attractive target for pathogens. As we showed in Chapter 2, many other viruses target
and inhibit RIPK1-mediated signaling. There is evidence that inhibition of RIPK1mediated pathways can enhance viral replication.

For example, RIPK1 kinase

activity-deficient mice had higher viral titers after infection with ZIKV and displayed
greater susceptibility to WNV infection relative to wild type mice (22,23). RHIM and
IPAM domains of MCMV M45 proteins were found to be important for inhibition of
RIPK1-mediated necroptosis (24). MCMV expressing M45 deficient of RHIM and/ or
IPAM displayed lower viral titers in mice possibly due to intact RIPK1-mediated
signaling. In light of this evidence, we hypothesized that RIPK1 expression would
have a deleterious effect on DENV replication.
Results and discussion
Several approaches were used to investigate the effect of RIPK1 expression on
DENV replication. First, we transfected a plasmid expressing Flag-RIPK1 in
HEK293T cells and cultured for 24 hrs. We then infected RIPK1-overexpressing cells
with DENV2. After an additional 48hrs supernatants from cells were collected. Cells
were lysed and total RNA and total protein were extracted. Western blot assays were
done to confirm RIPK1 overexpression and DENV infection. Total RNA was analyzed
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by qRT-PCR to quantify relative intracellular DENV RNA. Supernatants were used for
immuno-stained plaque assay (25) to determine the titer of infectious DENV particles.
Western blot results confirmed RIPK1 overexpression. However, we observed
a decrease in overexpressed RIPK1 levels with DENV infection (Fig 7A lanes 5,6 &
Fig 7B). We did not detect a difference in infectivity with overexpression of RIPK1 as
shown by the intensity of bands corresponding to DENV NS3 (Fig 7A lanes 4,5,6).
Relative intracellular DENV RNA levels increased by 69 hrs post-infection as
compared to 20hrs post-infection even with the overexpression of RIPK1 (Fig 7C). A
slight decrease in intracellular DENV RNA levels was observed with the
overexpression of RIPK1 as compared to pcDNA control plasmid at both 20 hrs and
69 hrs post-infection. Viral titers in the supernatants of cells where RIPK1 was
overexpressed were also slightly lower than in supernatants of control cell cultures at
20 hrs post-infection. However, neither of these differences (in intracellular viral RNA
or viral titers) was statistically significant.
We next hypothesized further ablation of RIPK1 will benefit DENV
replication. Thus, we next investigated the effect of endogenous RIPK1 expression on
DENV replication. We transfected either a RIPK1-specific small interfering RNA
(siRNA) or a scrambled siRNA as a control into HEK293T cells and subsequently
infected the cells with DENV2 (MOI=2). Cells were harvested and total RNA was
extracted at 24 hrs post-infection. qRT-PCR was done on total RNA to detect RIPK1
and DENV RNA levels. We observed ~ 70% reduction in RIPK1 transcript levels with
siRNA treatment relative to controls (untreated and control siRNA-treated),
confirming the efficient knockdown of RIPK1 (Fig 8A). However, we observed no
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change in DENV RNA levels (Fig 8B). These preliminary results demonstrate that
DENV replication is unaffected by RIPK1 knockdown. Experiments should be
repeated to confirm this conclusion.
Overall our results indicate that RIPK1 expression does not directly affect
DENV replication in vitro. However, further studies are needed before an important
effect can be excluded. Strikingly most of the evidence on increased viral replication
with inhibition of RIPK1-mediated signaling is from in vivo studies. Daniels et al.
observed higher viremia in mice deficient in RIPK1 following ZIKV infection,
however, they could not reproduce these results in vitro (24). Neither genetic nor
pharmacological ablation of RIPK1 had an impact on ZIKV replication in bone
marrow-derived macrophages or dendritic cells. These results indicate the inhibition of
RIPK1-mediated signaling has different effects on viral replication in vivo vs in vitro.
However, we evaluated DENV replication without inducing RIPK1 signaling by
adding external stimuli such as TNF⍺. Therefore, the effects of TNFR1 and TLR3
signaling pathways on DENV replication could be investigated since these pathways
are inhibited by DENV. DENV titers/ RNA could be measured upon TNF⍺ and poly
(I:C) stimulation with and without RIPK1 overexpression.
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Figure 7. DENV replication is not affected by RIPK1 overexpression. (A) Western
blot results of HEK293T cells transfected with either a Flag-RIPK1 plasmid (0.25µg
/0.75µg) or a pcDNA (0.75 µg) control plasmid followed by DENV2 infection.
Overexpressed RIPK1 levels were detected by a ⍺Flag antibody while DENV
infection was detected by probing with an ⍺NS3 antibody. β-actin was used as a
loading control. Data are representative of a minimum of 3 experiments. (B)
Densitometric analysis of RIPK1 band intensities normalized to β-actin levels from
(A). Results are from a single experiment and are representative of at least three
separate experiments. (C) RT-qPCR analysis of intracellular DENV RNA at 20 hrs and
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69hrs post-infection. (D) Plaque assay of culture supernatants from DENV2-infected
cells 20hrs following pcDNA or RIPK1 overexpression. Error bars represent standard
error of the mean of three technical replicates from two experiments per condition.
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Figure 8. DENV Replication is not affected by silencing of endogenous RIPK1.
RT-qPCR analysis of total RNA isolated from HEK293T cells untransfected (UNT) or
transfected with either a RIPK1-specific siRNA (RIPK1) or scrambled siRNA (-Ve)
followed by DENV infection for (A) RIPK1 mRNA or (B) intracellular DENV RNA
at 24hrs post-infection. Data are mean ± SD (n=2 experiments). UNF = uninfected.
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Materials and methods
Cell culture and virus infection
Huh7 ( a generous gifts from Dr. Kate Fitzgerald), HEK 293T (Dharmacon, Inc.) and
Vero, (obtained from American Type Culture Collection (ATCC)) were maintained in
Dulbecco's modified minimal essential medium and supplemented with 10% heatinactivated fetal bovine serum (Sigma-Aldrich), 1% penicillin-streptomycin (SigmaAldrich), 1% non-essential amino acids (Lonza) and 1% L-Glutamine solution
(Sigma-Aldrich). All cells were incubated in a humidified chamber at 37 °C and 5%
CO2. Prototype DENV strains DENV2 16681 was originally obtained from the
American Type Culture Collection. Virus titers were determined by immunostained
plaque assay on Vero cells (25,26)
Western Blot analysis

Cells were lysed in RIPA buffer freshly supplemented with a protease and phosphatase
inhibitor cocktail (Sigma-Aldrich). Lysates were incubated on ice for 30 min with
vortexing every 5 minutes and centrifuged at 10,000 rpm for 5 min at 4 °C.
Supernatants were used as total cell lysates. Protein concentrations were determined
using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific) following
manufacturer's instructions and measured using an Envision plate reader
(PerkinElmer). BOLT LDS Sample Buffer and Reducing Agent (Thermo Fisher
Scientific) were added to cell lysates at a final concentration of 1x and samples were
denatured at 70 °C for 10 min. Proteins were separated on 4–12% or 8% BOLT BisTris Plus gels (Thermo Fisher Scientific) and transferred onto nitrocellulose
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®
membranes using the Trans-Blot TurboTM RTA Mini Nitrocellulose Transfer kit

(Bio-Rad). Membranes were blocked in 5% milk in phosphate buffered saline with
0.1% Tween 20 for 1 h at room temperature (rt) followed by incubation with the
appropriate primary antibody overnight at 4 °C. Membranes were washed and
incubated with the appropriate secondary antibody diluted in blocking buffer for 1
hour at rt. For β-actin and GAPDH analysis, membranes were stained for 1 hour with
corresponding antibodies. Detection of blots was done using Amersham ECL Select
Western Blotting Detection Reagent (GE Healthcare Life Sciences) following the
manufacturer's guidelines, and images were captured with the ChemiDocTM XRS+
System (Bio-Rad). Detection and quantification of band intensities were performed
using Image Lab 5.1 (Bio-Rad).
Antibodies
The following primary antibodies were used for western blot experiments: anti-FlagHRP (sc-166355, Santa Cruz Biotechnology), anti-Caspase 3 (sc-56053, Santa Cruz
Biotechnology), anti-β-actin-HRP (ab20272, Abcam), anti-p-MLKL (ab187091,
Abcam), anti-GAPDH-HRP (MA515738), anti-DENV NS3 (GTX124252, GeneTex),
anti-RIPK1 (D94C12, Cell Signaling Technology), and anti-LC3B (2775S, Cell
Signaling Technology). Secondary antibodies used were goat anti-rabbit-HRP (32260,
Thermo Scientific) and anti-mouse-HRP (sc516102, Santa Cruz Biotechnology).
Plasmids and transfection
Overexpression of RIPK1 was done by transfecting 0.25µg or 0.75µg of a Flag-RIPK1
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plasmid (Addgene) or 0.75µg of a control plasmid (pcDNA) into HEK293T cells
using Genejuice transfection reagent (EMD Millipore, cat# 70967-3) according to
manufacturer’s protocols. siRNA targeting RIPK1 and siRNA negative control were
purchased from ThermoFisher Scientific. Transfection of cells with siRNA was
performed using Lipofectamine RNAiMAX transfection reagent according to the
manufacturer's instructions (Thermofisher Scientific).

Proteasome inhibition
DENV2-infected or uninfected Huh7 cells were treated with 1µM MG132 for 24 hrs
or 100nM Bortezomib for 6hrs. Control cells were treated with a similar concentration
of DMSO. Cells were harvested and analyzed by western blotting.

Autophagy inhibition
Cells transfected with Flag-RIPK1 and DENV NS2B3 were treated with 3.3mM 3MA
or an equal concentration of the vehicle control, EtOH, for 12 hrs. Cells were
harvested and RIPK1 levels detected by western blotting.

Lysosome inhibition
DENV2-infected or uninfected Huh7 cells were treated with 10µM Chloroquine for 24
hrs or 100nM Bortezomib for 6 hrs. Control cells were treated with a similar volume
of DMSO. Cells were harvested and analyzed by western blotting.
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Cell viability assay
Huh 7, Huh 7.5, Hek 293T and Vero cells were plated in a 96 well plate. Cells were
pretreated for 1hr with 20µM Nec-1 or DMSO. After 1 hr cells were infected with
DENV2 and cultured for 48hrs. Cells were then lysed by the addition of Cell titer Glo
reagent (Promega) diluted 1:4 in Phosphate buffered saline (PBS). Cell lysates were
transferred into a 96-well opaque plate and the luminescence was measured using an
Envision plate reader (PerkinElmer). Values were averaged from 3 biological
replicates and the values for uninfected DMSO-treated cells were defined as 100%.

Necroptosis assay
U937-DC-SIGN cells were plated in a 24-well plate and infected with DENV2
(MOI=5) for 42hrs. Cells were then treated with 20µM zVAD-FMK (Santa Cruz
Biotechnology), 50ng/ml TNF⍺ (Peprotech), and 10µM Smac mimetic (Fisher
Scientific) with and without 50µM Nec-1 (Sigma Aldrich) for 6 hrs. Cells were
harvested by centrifugation at 1600rpm for 5 minutes and lysed with RIPA buffer
supplemented with protease inhibitors. Cell lysates were analyzed by western blot.

RT-qPCR analysis
Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen).
Quantitative RT-PCR was performed using iTaq Universal probes 1-step kit (Biorad)
or iTaq Universal SYBR Green 1-step kit (Biorad) on a Bio-Rad CFX machine, and
gene expression was normalized to the β-actin expression level. Taqman gene
expression assays (RIPK1 and β-actin) were purchased from Thermofisher Scientific.
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DENV primers were purchased from Integrated DNA Technology (IDT) and RT-qPCR
was performed. Thermocycler protocol for PCR reactions was; 40 cycles of 10 min at
50°C, 3 min at 95°C, 15 sec at 95°C and 30 sec at 60°C. Similar concentrations of
total RNA were compared to detect relative DENV RNA in cell lysates based on a
standard curve calculated using primers for DENV2 (40).

DENV plaque assay
Virus titers were determined by immunostained plaque assay on Vero cells as
described in (25). First, serial 0.5 log dilutions of virus-containing supernatants were
added to Vero cells in a 96-well plate. After 2 hrs of incubation, overlay media
containing MEM and 2% carboxymethyl cellulose was added to restrict viral spread.
After 3 d, viral plaques were detected using anti-Dengue virus complex antibody
(MAB 8705, Millipore Sigma) followed by the secondary antibody, mIgH-HRP (906001, Southern Biotech). Spots were developed by the addition of the substrate solution
(TMB Elispot substrate, Mabtech #3651-10). Spots were counted by CTL ImunoSpot
analyzer.
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CHAPTER 5
Conclusion
Activation of innate immunity due to the detection of viral replication products
in the cell leads to the expression of hundreds of antiviral genes and proinflammatory
cytokines and chemokines that control the spread of the infection. Because of this
pivotal role in antiviral host defense, innate immune pathways are often targeted for
inhibition by viruses. As summarized in Chapter 2, several viral proteins, including
viral proteases, have been reported to modulate immune responses, allowing diverse
families of viruses to modify the intra and extra-cellular environment to promote
optimal conditions for replication and spread.
Here we have found that DENV significantly decreased RIPK1 protein levels
in infected cells. Overexpression of the DENV protease, NS2B3, was sufficient to
decrease RIPK1 levels demonstrating a direct role for NS3 in RIPK1 reduction. NS3
protease activity was fundamental for this effect, because the overexpression of a
catalytically inactive protease mutant (NS2B3-S135A) did not result in a significant
RIPK1 reduction. Additionally, both WT and protease mutant NS3 physically
interacted with RIPK1. Furthermore, DENV inhibited NF-kB activation downstream
of TNFR1 and TLR3 receptors by targeting RIPK1. Moreover, we detected DENV did
not induce necroptosis and further suppressed T/S/Z-induced necroptosis in U937-DCSIGN cells. DENV infection did not induce proteasomal/lysosomal degradation of
RIPK1. Finally, we did not detect a direct effect of RIPK1 on DENV viral replication.
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Implications of inhibition of RIPK1 signaling in DENV infection
RIPK1 is placed at a crucial point in controlling cell death and inflammation.
RIPK1-mediated signaling governs the outcome of signaling pathways initiated by
TNFR1, TLR3, TLR4 and RIG-I/MDA5. RIPK1 is involved in signaling for NF-kB
activation, MAPK and IRF3/7 phosphorylation. NF-kB induces pro-apoptotic genes as
well as pro-inflammatory cytokines and chemokines that are important for signaling
other immune cells. MAPK signals for AP-1 transcription, which induces the
expression of several important cytokines. IFN responses are critical for restricting
viral replication. IFNs further signal for the induction of hundreds of antiviral genes
via the JAK/STAT pathway. Apart from these outcomes, RIPK1 signaling is
implicated in several cell death mechanisms. RIPK1 is involved in driving extrinsic
apoptosis or necroptosis downstream of TNFR1, TLR3 and TLR4. Since all the abovementioned strategies act as anti-viral mechanisms, RIPK1 has emerged as an attractive
target for inhibition by viruses. This is exemplified by the breadth of RIPK1 inhibition
strategies that have evolved in numerous viruses. For example, HIV-1 and HRV-16
proteases cleave RIPK1 (1,2). Human HSV-1 proteins ICP6 and ICP10, MCMV M45
protein, EBV LMP1 protein, and HTLV-1Tax protein all block protein-protein
interactions of RIPK1 in signaling pathways by competitively binding to RIPK1 (3–6).
Additionally, HSV-1 ICP6 and MCMV M45 selectively degrade RIPK1 via the
autophagosome machinery (7). Furthermore, EBOV encodes miRNA that targets
RIPK1 and decreases its transcript levels (8). RIPK1 kinase-inactive mice exhibited
increased viral titers following ZIKV and VACV infection while displaying increased
susceptibility to WNV infection (9–11). These data indicate the importance of RIPK1
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inhibition in virus infections.
DENV stimulates immune responses via TLR7, TLR3, MDA5 and RIG-I.
DENV NS1 is known to stimulate TLR4 (12–14). These stimulations result in the
secretion of IFN-a/b that renders other host cells resistant to subsequent DENV
infections (15). The secretion of TNFa during DENV infection results in the
stimulation of TNFR1. TNFa stimulation results in the activation of dendritic cells
leading to increased expression of cell surface costimulatory and activation molecules
and enhancement of their antigen-presenting function (16–18). However, DENV has
been reported to block the activation of infected dendritic cells, which may reduce
priming of CD4+ or CD8+ T cells. Interestingly, non-infected bystander monocytes
and dendritic cells still can become activated during DENV infection (19). Gene
expression analysis of acute dengue patients revealed lower levels of expression of
genes associated with antigen processing, antigen presentation and T cell activation in
DHF than in DF (20). Since RIPK1 is involved in TNFa signaling, we can speculate
that inhibition of RIPK1 by DENV may decrease dendritic cell activation and
maturation. Consequently, impaired antigen presentation and functionality of DENVinfected DCs may reflect a viral evasion strategy to impede host immune responses.
DENV infection was shown to block NF-𝛋B activation downstream of TLR3
signaling, resulting in downregulated cytokine production (21). However, the
mechanism by which DENV caused these altered responses had not been defined.
Here, we demonstrated that DENV infection diminished NF-𝛋B activation in response
to poly I:C stimulation by targeting and decreasing RIPK1 levels downstream of
TLR3. The effect of the impairment of this pathway on IFN production, apoptosis and
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necroptosis should be further investigated.
There is evidence of the importance of RIPK1 function in T and B cells as
well. For example, robust cross-priming of CD8+ T cells required intact RIPK1
signaling and NF-kB-induced transcription in dying cells (22). Another study found a
kinase-independent function of RIPK1 that is important for mature T-cell survival and
proliferation (23).

RIPK1 function is also reported to be critical in B cell

development; TLR4-stimulated RIPK1-/- B cells exhibited impaired NF- κB activation
(24). Therefore, DENV-mediated inhibition of RIPK1 in T and B cells may play a role
in altering critical immune pathways in these cells. Expanding our assays to study T
and B cells may help decipher additional important roles of RIPK1-mediated signaling
in DENV infection.
RIPK1 is involved in type I IFN production downstream of the RIG-I/MDA-5
pathway. Even though some studies could not detect a direct role of RIPK1 in IFNb
production, we were able to detect a convincing positive effect of RIPK1
overexpression on phosphorylation of IRF3 by western blotting. Additionally, we
detected increased IFNb transcript levels with overexpression of RIPK1. These
preliminary findings suggest a positive effect of RIPK1 on type I IFN production
which is known to directly downregulate viral replication. Thus, RIPK1 inhibition
becomes extremely advantageous for DENV. Further studies could be carried out to
test if DENV-mediated RIPK1 inhibition contributes to downregulated type I IFNs
downstream of RIG-I/MDA5. However, even though it is not the primary route, NFkB also induces IFNb and IFNg (25–28). Thus, further investigations are needed to
understand if DENV inhibits the secretion of IFNb and IFNg by inhibiting NF-kB
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pathway downstream of TNFR1 and TLR3.

Apoptosis in DENV infection
Liver injury is a common finding in DENV infection and can lead to organ
failure. Apoptosis of hepatocytes following DENV infection is believed to contribute
to this phenomenon (29). Apoptotic cells have been found in the liver, brain and lung
tissues from autopsy examinations of DHF and DSS patients (30). The mechanisms by
which DENV induces apoptosis are not known and may differ between different cell
types. Recent findings show a protective role of RIPK1 against TNFɑ-mediated
apoptosis in hepatocytes (31,32). RIPK1 knockout mice showed enhanced sensitivity
to TNFα-mediated apoptosis and inflammation. The induction of NF-𝛋B target gene
transcripts was also suppressed in these mice. Therefore, we speculate that the loss of
RIPK1 during DENV infection may sensitize hepatocytes to cell death and
inflammation, which could contribute to liver injury in DHF.

Necroptosis in DENV infection
Since viruses rely on the host cell machinery to propagate, host cell death is
detrimental for viruses. Necroptosis is emerging as an important anti-viral mechanism
for restricting viral replication. Apart from restricting viral propagation by destroying
the cell, necroptosis is implicated in releasing intracellular DAMPs and PAMPs and
promoting inflammation (33). RIPK1 kinase activity is important for necroptosis
induction. Therefore, viruses target RIPK1 for inhibiting necroptosis. There is
evidence that CMV, EBV and HIV-1 viruses inhibit necroptosis by targeting RIPK1
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using various mechanisms as shown in Fig 3 of chapter 2.

We observed that

necroptosis was not induced in vitro upon DENV infection. Furthermore, DENV was
able to suppress artificially induced necroptosis downstream of TNFRI, possibly due
to low levels of RIPK1. However, whether DENV stimulation of TLR3/4 leads to
necroptosis is still unknown. Further efforts should address if necroptosis downstream
of TLR3/4 contributes to dengue disease pathogenesis.

The effect of RIPK1 on DENV replication
There is evidence supporting a direct correlation between peak viremia titer
and dengue disease severity (34) suggesting that efficient viral replication contributes
to dengue disease. Staining for DENV structural proteins and viral RNA in human
autopsies from dengue patients confirmed viral replication in lymph nodes, spleen,
lung and liver (19). This excessive viral replication reflects the capability of DENV to
suppress innate immune mechanisms efficiently. Thus, inhibition of RIPK1-mediated
signaling, may also benefit DENV replication.
Contrary to our expectations, we did not observe decreased intracellular viral
RNA or infectious viral titers in the supernatants of cells when RIPK1 was
overexpressed. Similarly, studies did not indicate a significant increase in intracellular
viral RNA when endogenous RIPK1 was knocked down. Taken together, our
observations do not support a direct link of RIPK1 levels affecting DENV replication.
However, these experiments were done without stimulating the TNFR1. Thus, the
effect of TNFa-induced NF-kB activation on DENV replication should be further
investigated. For this purpose, relative intracellular viral RNA and infectious viral

127

titers in the supernatants of cells could be analyzed with overexpression of RIPK1 in
the presence or absence of TNFa stimulation. Furthermore, the cytokines expressed by
the induction of NF-kB could be more important for setting an antiviral state in the
intact tissue/organism by activating uninfected bystander cells and T and B cells. This
effect is hard to achieve in cell culture. Also, some of the cell lines we used may not
effectively secrete inflammatory cytokines. Thus, it would be plausible to use PBMC
from patients for testing the effect of RIPK1 on viral replication. Expanding our
findings using human dendritic cell subsets isolated from blood or tissues will be
important to characterize the full spectrum of immune responses mediated by RIPK1
in DENV infection.

DENV strain-specific effects on RIPK1
Western blot results following infections with different strains of DENV revealed
strain-specific effects on RIPK1 levels. DENV1 strain Hawaii, DENV2 strain 16681,
and DENV2 strain NGC exhibited a significant decrease in RIPK1 levels in Huh7
cells. DENV1 strain C0245/96, DENV3 strain CH53489, and DENV3 strain
C0360/96 displayed decreased RIPK1 levels, but this was not statistically significant.
Interestingly, neither DENV4 strain 814669 nor H241 decreased RIPK1 significantly.
These differences in effects on RIPK1 could be attributed to structural differences in
the DENV protease complex, NS2B3. Crystal structure analysis of DENV protease
complexes of DENV1, DENV2 and DENV4 revealed serotype-specific differences
(35–37). Differences in substrate binding and substrate catalysis have also been
attributed to structural differences between DENV proteases (35). Conformational
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changes undergone by NS2B upon substrate binding account for additional variation.
Differences in virulence in naturally circulating DENV strains and serotypes are
speculated to contribute to dengue disease. For example, a study done on children with
acute DENV infections reported secondary DENV2 caused more severe disease than
DENV1 or DENV4, suggesting that virus genotype affects outcome (34). Altogether,
our data indicate DENV strain-specific effects on RIPK1 reduction which could be
responsible for differences in virulence exhibited by virus strains.

Limitations and future experiments
One limitation that was encountered in the study was the lack of availability of
some commercial antibodies. None of the antibodies used could detect a cleaved
product of RIPK1. Therefore, we concluded that the resulting fragment may be too
small to detect by western blotting or may be further degraded. However, the exact
mechanism of NS3-mediated cleavage/degradation of RIPK1 remains to be elucidated.
We could not find a commercial antibody that could detect pro and cleaved caspase 8
efficiently. Because of this, understanding the role of RIPK1 in caspase 8 activation
was limited.
Our studies were primarily done on immortalized cell lines and monocytederived dendritic cells. There are some caveats in using cell lines for understanding
intricate biological signaling pathways. Generally, our findings are limited to one cell
type, in cell culture, whereas many cells orchestrate to contribute to the outcome of
infection in vivo. Even though some cell lines have intact NF-kB signaling, they may
not secrete cytokines efficiently. RIPK1 signaling is regulated by cell-intrinsic as well
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as cell-extrinsic stimuli. Extra-cellular stimuli under natural conditions would be better
reflected in in vivo models. Therefore, our study could be extended to PBMCs and
include the investigation of the effects of NF-kB inhibition on cytokine secretion in
infected as well as bystander cells. Similar studies have been done to investigate the
effect of RIPK1 inhibition in other diseases. For example, qRT-PCR analysis of
peripheral blood leukocytes from patients with Systemic Lupus Erythematosus
revealed lower RIPK1 transcript levels than from healthy individuals. Serum TNFa
and IL-2 levels were also significantly lower in the SLE patients than in the healthy
individuals (38).
Additionally, it could be of interest to study the effect of “ADE” on RIPK1
inhibition and cytokine expression by DENV. This could be achieved by infection of
cells in the presence of cross-reactive DENV antibodies. Furthermore, it would be
interesting to see in vivo effects of RIPK1 inhibition on DENV at an organismal level.
However, DENV fails to antagonize mouse immune responses. WT mice usually do
not sustain DENV replication or develop disease symptoms as seen in DHF (15,40).
Therefore, understanding immune evasion strategies and the disease pathogenesis of
DENV has been mostly limited to in vitro and ex vivo assays.
We observed a physical interaction between RIPK1 and DENV NS3. However,
we do not know what motifs of both proteins are important for this interaction. RIPK1
is known to interact with other RHIM domain-containing proteins. Some viral proteins
are known to contain RHIM-like domains. To investigate important motifs for this
interaction, co-immunoprecipitation studies could be done with overexpression of
DENV NS2B3 and RHIM-mutant RIPK1 plasmid. Furthermore, we do not know if
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any other proteins are involved in the RIPK1-NS3 complex. For example, DENV NS5
is known to interact with STAT2 and proteins of the ubiquitination machinery,
resulting in STAT2 ubiquitination and degradation (41). Given that RIPK1 is posttranslationally modified by ubiquitination (42), the involvement of other proteins in
the NS3-RIPK1 complex can be speculated. Mass spectrometry and proteomics
analysis could reveal such complex formation during DENV infection. MCMV and
HSV-1 viral proteins contain “IPAM” motifs that induce protein aggregates. RIPK1
was shown to aggregate and get degraded in the presence of MCMV M45 protein and
HSV-1 ICP6 protein. Such effects have not been tested in DENV so far. Therefore, it
would be interesting to check if DENV could induce host proteins to aggregate
including RIPK1.
Additionally, the effect of RIPK1 inhibition on uninfected bystander cells
should be investigated. Since RIPK1 inhibition leads to less cytokine secretion and
inhibition of necroptosis, we can speculate that fewer bystander cells would be
stimulated/activated, rendering them susceptible to DENV infection.
There is evidence of a link between dysregulation of RIPK1 and the
pathogenesis of inflammatory and neurogenerative diseases such as multiple sclerosis
(MS), ALS, Alzheimer’s disease and inflammatory bowel disease (43). RIPK1 is
emerging as a promising therapeutic target for treating such diseases. DENV infection
in patients with such pre-existing conditions may be more likely to result in severe
dengue disease due to further inhibition of RIPK1-mediated signaling. Thus,
understanding the inhibition of RIPK1 signaling in viral disease pathogenesis will be
helpful in treating other diseases as well.
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Additional in silico analyses could be performed to investigate various aspects
of NS3-RIPK1 interaction. DENV protease is known to recognize and cleave substrate
sequences having a small amino acid following two basic residues (44, 45). A manual
homology search for such sequences in RIPK1 could be carried out using
bioinformatic tools such as DNASTAR Laser gene software. Site directed mutagenesis
could be performed to mutate putative cleavage sites on RIPK1 experimentally.
Further co-transfection experiments could be performed using DENV NS2B3 and
plasmids encoding mutated RIPK1, which will be helpful for verifying if DENV NS3
cleaves RIPK1.
Viral proteins are known to interact with RIPK1 via RHIM domains. For
example, CMV M45 protein interacts with RIPK1 via the RHIM domain.
Furthermore, CMV M45 and HSV-1 ICP6 proteins induce RIPK1 aggregation and
degradation via IPAM motif. Therefore, it would be interesting to investigate if such
motifs exist in DENV NS3. Therefore, in silico analyses such as sequence
comparisons and homology search for RHIM and IPAM motifs could be done. These
analyses will potentially uncover DENV NS3 interactions between other RHIM
containing host proteins such as TRIF
In summary, this research has identified RIPK1 as a novel target of DENV
NS3. These findings expand the knowledge of strategies used by DENV to evade
innate immune responses. Manipulation of host cell RIPK1 by DENV may contribute
to the disease pathogenesis as illustrated by model I and II.
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Figure 1. Model 1: Cell-intrinsic effects of RIPK1 inhibition by DENV. DENV
NS3 protein interacts with and decreases RIPK1 levels. TNFR1- and TLR3-stimulated
NF-kB activation is impaired due to the NS3-mediated RIPK1 reduction. This may
result in the downregulation of many antiviral genes resulting in decreased production
of cytokines and chemokines. Cell death downstream of TNFR1 is also blocked by
DENV due to decreased RIPK1 levels. This may result in increased cell survival
allowing more efficient viral replication. The inhibition of necroptosis may also
suppress the release of DAMPs and PAMPs from the cell.
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Figure 2. Model II: The effects of RIPK1 inhibition at a tissue/organism level.
Inhibition of NF-kB activation by DENV may result in downregulated
cytokine/chemokine/IFN secretion. Inhibition of necroptosis may result in cell
survival, benefiting viral replication. These effects may result in increased virus
production. Bystander cell activation and recruitment of T and B cells may be
negatively affected by the inefficient cytokine/chemokine production. Uninfected cells
could become susceptible to further infection by DENV. Therefore, controlling virus
infection may be unsuccessful. The virus may spread into other cells/tissues/organs.
Taken together, increased viremia and altered immune responses may contribute to
severe dengue disease.
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